

Please type a plus sign (+) inside this box →

+

UTILITY PATENT APPLICATION TRANSMITTAL

Only for new nonprovisional applications under 37 C.F.R. §1.53(b)

Attorney Docket No.

PC10489A

First Named Inventor or Application Identifier

Miroslav Blumenberg

Title

Genes and Polynucleotides Associated with Ultraviolet Radiation-Mediated Skin Damage and Uses Thereof

Express Mail Label No.

By Hand

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 43]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference in Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 11.3) [Total sheets 3]
4. ☐ Oath or Declaration [Total pages]
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☒ Computer Readable Copy - 1 diskette
 - b. ☒ Paper Copy (identical to computer copy) - 24 pp.
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR §3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ *Small Entity ☐ Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☒ Other: Priority Claim
U.S. Provisional application serial No. 60/155,029 filed September 20, 1999

*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____

Prior application information: Examiner _____ Group/Art Unit: _____

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☒ Correspondence address below

Name	Paul H. Ginsburg				
Address	Pfizer Inc				
Address	235 East 42nd Street, 20th Floor				
City	New York	State	New York	Zip Code	10017-5755
Country	United States Of America	Telephone	(212)573-2369	Fax	(212)573-1939

NAME (Print/type)	Alan L. Koller	Registration No. (Attorney/Agent)	37,371
Signature	<i>Alan L. Koller</i>	Date	September 11, 2000

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1
These are the fees effective October 1, 1997.

Small Entity payments must be supported by a small entity statement.
Otherwise large entity fees must be paid. See Forms PTO/SB/09-12

See 37 C.F.R. §§ 1.27 and 1.28

Total Amount of Payment (\$2948.00)

Complete if Known

Application Number	To be assigned
Filing Date	September 11, 2000
First Named Inventor	Miroslav Blumenberg
Examiner Name	To be assigned
Group/Art Unit	To be assigned
Attorney Docket No.	PC10489A

METHOD OF PAYMENT (check one)

1. ☒ The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-1445

Deposit Account Name Pfizer Inc

☒ Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17 ☐ Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance

2. ☐ Payment Enclosed:
☐ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
101	690	201	345	Utility filing fee	690
106	310	206	155	Design filing fee	
107	480	207	240	Plant filing fee	
108	690	208	345	Reissue filing fee	
114	150	214	75	Provisional filing fee	
SUBTOTAL (1) (\$)					690.00

2. EXTRA CLAIM FEES

	Extra Claims	Fee from below	Fee Paid
Total Claims 53 - 20** = 33 X 18 =	33	18	594
Independent Claims 21 - 3** = 18 X 78 =	18	78	1404
Multiple Dependent 260 =	260		260

** or number previously paid, if greater; For Reissues, see below

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
103	18	203	9	Claims in excess of 20	
102	78	202	39	Independent claims in excess of 3	
104	260	204	130	Multiple dependent claim, if not paid	
109	78	209	39	**Reissue independent claims over original patent	
110	18	210	9	**Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2) (\$)					2258.00

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late fee or oath	
127	50	227	25	Surcharge-late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	380	216	190	Extension for reply within second month	
117	870	217	435	Extension for reply within third month	
118	1,360	218	680	Extension for reply within fourth month	
128	1,850	228	925	Extension for reply within fifth month	
119	300	219	150	Notice of Appeal	
120	300	220	150	Filing a brief in support of an appeal	
121	260	221	130	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,210	241	605	Petition to revive - unintentional	
142	1,210	242	605	Utility issue fee (or reissue)	
143	430	243	215	Design issue fee	
144	580	244	290	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	790	246	395	Filing a submission after final rejection (37 CFR 1.129(a))	
149	760	249	380	For each additional invention to be examined (37 CFR 1.129(b))	
Other Fee (specify)					
Other Fee (specify)					

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Type or Printed Name Alan L. Koller

Signature *Alan L. Koller*

Date

September 11, 2000

Complete (if Applicable)

Reg Number 37,371

Deposit Account User ID 16-1445

BY HAND

Box-Sequence

**Genes And Polynucleotides Associated With Ultraviolet
Radiation-Mediated Skin Damage And Uses Thereof**

This application claims priority from provisional application Serial No. 60/155,029, filed September 20, 1999, which is incorporated herein by reference in its entirety.

5

1. Field of the Invention

The invention provides novel polynucleotides, and their encoded gene products, that are expressed in skin cells, particularly keratinocytes, and methods of using the same. Specifically, the present invention relates to novel protein kinases that are c-Jun N-terminal kinase kinase kinases (JNKKKs). In addition, the invention provides methods of using the novel polynucleotides and their encoded products in drug discovery, particularly in screening for drugs that can reduce ultraviolet light-induced damage of the skin, inflammation and psoriasis, and drugs that can enhance wound healing.

10

2. Background of the Invention

Many extracellular signals, such as light, growth factors, cytokines and chemical or physical stresses, activate multi-tiered kinase cascades in the cytoplasm of cells. For example, a growth factor such as epidermal growth factor (EGF) will bind to its cognate receptor on the cell surface, thereby activating the intercellular protein ras, which is associated with the cytoplasmic portion of the cell surface receptor. Ras phosphorylates and thereby activates raf1, a mitogen-activated protein kinase kinase kinase (MAPKKK). Raf1 then induces (also by phosphorylation) the activation of mitogen-activated protein kinase kinases (MEKs), which in turn phosphorylate extracellular signal regulated kinases (ERKs). When phosphorylated, ERKs translocate to the nucleus where they phosphorylate and thus activate transcription factors such as stress activated protein kinase 1 (SAP1) and ternary complex factor Elk1. See, e.g., Fanger et al., 1997, Current Opin. Genet. Dev. 7:67-74.

15

Stress (such as heat and ultraviolet (UV) light) and cytokines (such as TNF- and IL-1) activate their own sets of kinase-kinase-kinases, termed JNKKKs. These, in turn, act on specific JNKs, which activate c-Jun-N terminal kinase (JNK) and p38. The last two kinases enter the nucleus, where they phosphorylate and activate transcription factors. See, e.g., Diene et al., 1997, PNAS 94:9687-92.

20

Most of the initial events in the cellular responses to different stresses have not been elucidated so far. However, it is clear that different extracellular signals activate different members of the JNKKK family. Thus, some JNKKKs are specifically responsive to TNF- α , others to osmotic shock, yet others to UV illumination. Diene et al., 1997, above; Raingeaud et al., 1995, J. Biol. Chem. 270:7420-6.

25

Skin cells such as keratinocytes are particularly susceptible to ultraviolet radiation damage. However, very little is known about how keratinocytes respond to ultraviolet radiation stress. Manipulation of keratinocyte responses to environmental stress could result

30

35

in therapies for a wide variety of skin disorders, as well as cosmetic uses.

Therefore, there is a great need in the art to elucidate the components involved in keratinocyte signal transduction that can be used as targets for drug screening. Accordingly, this invention provides several novel JNKKKs expressed by keratinocytes and involved in the cellular response to ultraviolet radiation, and uses thereof.

3. Summary of the Invention

The present invention relates to polynucleotide molecules having nucleotide sequences that encode portions of several novel JNKKK gene products including an MLK4 kinase, a PAK4 kinase, a PAK5 kinase, and a YSK2 kinase, as well as the amino acid sequences encoded by these polynucleotide sequences. The present invention further relates to polynucleotide molecules having nucleotide sequences that encode a PAK5 kinase.

In one aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human MLK4 gene product. In a preferred embodiment, the portion of the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:1.

The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:1. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:2.

The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned MLK4-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the MLK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human MLK4 gene product or MLK4-related homologous polypeptide of the present invention. In a specific though non-limiting embodiment, the present invention provides a polynucleotide molecule consisting of a nucleotide sequence encoding a peptide fragment consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:2.

In another aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK4 gene. In a preferred embodiment, the portion of the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:3.

The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID

NO:3. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:4.

5 The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK4-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the PAK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK4 gene product or PAK4-related homologous polypeptide of the present invention. In a specific though non-limiting
10 embodiment, the present invention provides a polynucleotide molecule consisting of a nucleotide sequence encoding a peptide fragment consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:4.

In another aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK5 gene product. In a
15 preferred embodiment, the portion of the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:6 comprises the nucleotide sequence of SEQ ID NO:5.

In another aspect, invention provides an isolated polynucleotide molecule comprising
20 a portion of the nucleotide sequence of the human PAK5 gene, which portion encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:8. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:8 comprises the nucleotide sequence of SEQ ID NO:7.

The present invention further provides an isolated polynucleotide molecule that is
25 homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:7. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:6 or SEQ ID NO:8.

In another aspect, the invention provides an isolated polynucleotide molecule
30 comprising a nucleotide sequence encoding the complete human PAK5 gene product having the amino acid sequence of SEQ ID NO:10. In a preferred embodiment, the polynucleotide molecule comprises the nucleotide sequence of SEQ ID NO:9 from nt 199 to nt 2244, which represents the ORF of the cDNA. In another non-limiting embodiment, the isolated polynucleotide molecule encoding the complete human PAK5 gene product comprises the
35 nucleotide sequence of the ORF of SEQ ID NO:11 from nt 6125 to nt 17,433.

The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID

NO:9 or SEQ ID NO:11.

The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK5-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the PAK5-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK5 gene product or PAK5-related homologous polypeptide of the present invention.

In another aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human YSK2 gene product. In a preferred embodiment, the portion of the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:12.

The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:12. The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:13.

The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned YSK2-related polynucleotide molecules of the present invention. In a preferred embodiment, the substantial portion of the YSK2-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human YSK2 gene product or YSK2-related homologous polypeptide of the present invention. In a specific though non-limiting embodiment, the present invention provides a polynucleotide molecule consisting of a nucleotide sequence encoding a peptide fragment consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:13.

The present invention further provides compositions and methods for cloning and expressing any of the polynucleotide molecules of the present invention, including cloning vectors and expression vectors comprising any of the polynucleotide molecules of the present invention, as well as transformed host cells and novel strains or cell lines derived therefrom comprising any of the polynucleotide molecules, cloning vectors or expression vectors of the present invention. In a non-limiting embodiment, the present invention provides a recombinant expression vector comprising a polynucleotide molecule of the present invention in operative association with one or more regulatory elements for expression of the polynucleotide molecule.

Also provided by the present invention is a substantially purified or isolated polypeptide encoded by a polynucleotide molecule of the present invention. In a specific

though non-limiting embodiment, the polypeptide is a portion of a human MLK4 gene product comprising the amino acid sequence of SEQ ID NO:2. In another specific though non-limiting embodiment, the polypeptide is a portion of a human PAK4 gene product comprising the amino acid sequence of SEQ ID NO:4. In another specific though non-limiting embodiment, the polypeptide is a portion of a human PAK5 gene product, comprising the amino acid sequence of either SEQ ID NO:6 or SEQ ID NO:8, or is the entire human PAK5 gene product comprising the amino acid sequence of SEQ ID NO:10. In another specific though non-limiting embodiment, the polypeptide is a portion of a YSK2 gene product, comprising the amino acid sequence of SEQ ID NO:13.

The present invention also provides substantially purified or isolated polypeptides that are homologous to the portions of the human MLK4, PAK 4, PAK5 and YSK2 gene products of the present invention. The present invention also provides a substantially purified or isolated polypeptide that is homologous to the complete human PAK5 gene product of the present invention. The present invention further provides substantially purified or isolated peptide fragments of the MLK4, PAK4, and PAK5 gene products of the present invention, and substantially purified or isolated peptide fragments of the YSK2 gene product of the present invention that have the first six amino acids of SEQ ID NO:13.

The present invention also provides a method of preparing a substantially purified or isolated portion of a human MLK4, PAK4, PAK5 or YSK2 gene product, or a substantially purified or isolated human PAK5 gene product, or a homologous peptide, or peptide fragment of the present invention, comprising culturing host cells transformed with a polynucleotide molecule or vector of the present invention under conditions conducive to the expression therefrom of the polypeptide or peptide fragment of the invention, and recovering the polypeptide or peptide fragment in substantially purified or isolated form from the cell culture.

Also provided are antibodies specific for the MLK4, PAK4, PAK5 or YSK2 gene product, homologous peptide, or peptide fragment of the present invention, and methods of detecting the MLK4, PAK4, PAK5 or YSK2 gene product, homologous peptide, or peptide fragment of the present invention in a sample. Still another aspect of the invention provides methods of identifying compounds that bind to the MLK4, PAK4, PAK5 or YSK2 gene product, homologous peptide, or peptide fragment of the present invention.

The present invention also provides methods of detecting an MLK4, PAK4, PAK5 or YSK2-related polynucleotide in a sample, comprising contacting the sample with a compound that binds to and forms a complex with the particular polynucleotide for a period of time sufficient to form the complex, and detecting the complex, so that if a complex is detected, the MLK4, PAK4, PAK5 or YSK2-related polynucleotide, respectively, is detected. In a non-limiting embodiment, the method comprises contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the particular polynucleotide

under such hybridization conditions, and amplifying the annealed polynucleotides, so that if a particular polynucleotide is amplified, the MLK4, PAK4, PAK5 or YSK2-related polynucleotide, respectively, is detected.

The invention further provides a method of screening for compounds that affect the cellular levels of a JNKKK gene product, comprising: (a) applying a test compound to a test sample; (b) determining the cellular levels of at least one gene product in the test sample, wherein the gene product is from a gene comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11 and 12; and (c) comparing the levels of the gene product in the test sample with that in a reference sample; wherein a specific change in the cellular levels of the gene product in the test sample as compared to the reference sample indicates that the test compound affects the cellular levels of gene product from a JNKKK gene. In a preferred embodiment, the method further comprises the step of applying a stress event to the test sample and determining the effect of the test compound on the response of the test sample to the stress event.

The invention further provides a method of screening for compounds that affect the expression of a gene that encodes a JNKKK gene product, comprising: (a) applying a test compound to a test sample; (b) determining the expression level of at least one gene in cells of the test sample, wherein the gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11 and 12; and (c) comparing the expression level of the gene in the test sample with that in a reference sample; wherein a specific change in the expression of the gene in the test sample as compared to the reference sample indicates that the test compound affects the expression of the gene. In a preferred embodiment, the method further comprises the step of applying a stress event to the test sample and determining the effect of the test compound on the gene expression response of the test sample to the stress event.

Still another aspect of the invention provides a method of screening for compounds that affect the activity of a JNKKK gene product, the method comprising: (a) applying a test compound to a test sample; and (b) determining the activity of a JNKKK gene product in the test sample versus a reference sample, wherein the JNKKK gene product comprises an amino acid sequence selected from the group consisting of: SEQ ID NOS: 2, 4, 6, 8, 10 and 13; wherein a test compound that alters the JNKKK gene product activity in the test sample as compared to the reference sample is identified as a compound that affects the activity of the JNKKK gene product. In a preferred embodiment, the method further comprises the step of applying a stress event to the test sample and determining the effect of the test compound on the response of the test sample to the stress event.

4. Brief Description of the Figures

Figure 1 is a schematic diagram illustrating the structure of the PAK5 gene.

Figure 2 is a Northern Blot illustrating the tissue-specific expression of MLK4, PAK4 and PAK5 genes. Messenger RNA was isolated from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas, run on a denaturing gel in the indicated lanes, and blotted to a membrane. The same blot was sequentially hybridized (after stripping between

5 hybridizations) to labeled 150 base pair probes specific for MLK4, PAK4 and PAK5.

Figure 3 shows the induction of YSK2 and PAK5 genes in response to ultraviolet radiation. Figure 3A is a Northern blot of mRNA from keratinocytes untreated (control) or treated (control) with UV-C radiation for 5 days. The blot was hybridized to a 150 base pair probe specific for the YSK2 gene. Figure 3B shows a differential display experiment

10 designed to examine any change in expression levels of the PAK4 and PAK5 genes in response to UV-A light. Keratinocytes were exposed to UV-A light for 0, 6 or 24 hours, harvested and mRNA analyzed. Bands corresponding the PAK4 and PAK5 message are indicated.

5. Detailed Description of the Invention

15 The present invention relates to identification and characterization of polynucleotide molecules expressed in skin keratinocytes, which polynucleotide molecules encode JNKKK polypeptides. Because the kinase domains of JNKKKs are conserved in sequence, primers can be designed for reverse transcription-polymerase chain reaction (RT-PCR) detection of virtually all the JNKKKs expressed by a cell or cell type. In one embodiment, the primer pair

20 5'-ATGCA(CA)CANGA(CT)AT(ACT)AA(AG)-3' (SEQ ID NO:14) (forward) and 5'-GCNAC(CT)TCNGGNGCCATCCA-3' (SEQ ID NO:15) (reverse) can be used to detect novel JNKKKs. The product of using the primer pair is a common 150 bp segment. As discussed below in the Example sections, a primer pair was used to screen human epidermal keratinocyte mRNA, and polynucleotides encoding several novel JNKKKs were discovered.

25 In addition, the present invention relates to the discovery that the JNKKKs encoded by these polynucleotides are involved in the cellular response to stress such as ultraviolet (UV) light. By way of example, the invention is described in the sections below for an isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the MLK4 open reading frame (ORF) (SEQ ID NO:1); for an isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the PAK4 ORF (SEQ ID NO:3); for an isolated

30 polynucleotide molecule comprising the nucleotide sequence of a portion of the PAK5 ORF (SEQ ID NO:5); for another isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the PAK5 gene (SEQ ID NO:7); for an isolated polynucleotide molecule comprising the nucleotide sequence of the cDNA encoding the PAK5 gene product (SEQ ID NO:9, ORF from nt 199-2244); for an isolated polynucleotide molecule comprising the nucleotide sequence of the PAK5 gene (SEQ ID NO:11, ORF from nt 6125-17433); and for an isolated polynucleotide molecule comprising the nucleotide sequence of a portion of the

35

YSK2 ORF (SEQ ID NO:12).

5.1. Polynucleotide Molecules

As used herein, the terms "polynucleotide molecule," "polynucleotide sequence," "coding sequence" "open-reading frame (ORF)", and the like, are intended to refer to both
5 DNA and RNA molecules, which can either be single-stranded or double-stranded. A coding sequence or ORF can include but is not limited to prokaryotic sequences, cDNA sequences, genomic DNA sequences, and chemically synthesized DNA and RNA sequences. A "gene product" is intended to refer to a product encoded by a gene, including the transcribed RNA message (including exons and introns), the spliced messenger RNA (mRNA), and the
10 translated protein product encoded by the respective mRNA.

Production and manipulation of the polynucleotide molecules and oligonucleotide molecules disclosed herein are within the skill in the art and can be carried out according to recombinant techniques described, among other places, in Maniatis et al. 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
15 NY; Ausubel et al., 1989, Greene Publishing Associates & Wiley Interscience, NY; Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Innis et al. (eds), 1995, PCR Strategies, Academic Press, Inc., San Diego; and Erlich (ed), 1992, PCR Technology, Oxford University Press, New York, all of which are incorporated herein by reference.

20 5.1.1. MLK4-related Polynucleotide Molecules

The present invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human MLK4-related gene product. In a preferred embodiment, the portion of the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2. In a non-limiting embodiment, the isolated polynucleotide
25 molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:1.

The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:1. The term "homologous" when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by
30 SEQ ID NO:1, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code (i.e., a degenerate variant); or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:1, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK), and
35 which hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 under moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M

NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.2XSSC/0.1% SDS at 42°C (see Ausubel et al. (eds.), 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3), and is useful in practicing the invention. In a preferred embodiment, the
5 homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1 x SSC/0.1% SDS at 68°C (Ausubel et al., 1989, above), and is useful in practicing the
10 invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule consisting of the nucleotide sequence of SEQ ID NO:1, and is useful in practicing the invention.

As used herein, an MLK4-related polynucleotide molecule is “useful in practicing the
15 invention” where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the MLK4 gene product from a eukaryotic cell; or (ii) can detect the presence of the MLK4 transcript in a test sample; or (iii) can enable a method for altering the regulation or expression of the endogenous MLK4 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional
20 activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide sequence of the MLK4 ORF in a eukaryotic cell using standard amplification techniques such as PCR. Such homologous polynucleotide molecules can include naturally occurring MLK4 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example,
25 mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated MLK4 alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:2. As used herein to
30 refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a portion of an MLK4 gene product from a human, the term “homologous” means a polypeptide comprising the amino acid sequence of SEQ ID NO:2, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, wherein the resulting amino acid sequence has at least about 70%, more preferably
35 at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:2 wherein amino acid sequence identity is determined by any standard amino acid sequence identity algorithm, such as, e.g., BLASTP (GENBANK), where the resulting

polypeptide is useful in practicing the invention. Conservative amino acid substitutions are well known in the art. Rules for making such substitutions include those described by Dayhof, M.D., 1978, Nat. Biomed. Res. Found., Washington, D.C., Vol. 5, Sup. 3, among others. More specifically, conservative amino acid substitutions are those that generally take place within a family of amino acids that are related in the acidity, or polarity of their side chains. Genetically encoded amino acids are generally divided into four groups: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan and tyrosine are also jointly classified as aromatic amino acids. One or more replacements within any particular group, e.g., of a leucine with an isoleucine or valine, or of an aspartate with a glutamate, or of a threonine with a serine, or of any other amino acid residue with a structurally related amino acid residue, e.g., an amino acid residue with similar acidity, or polarity or with similarity in a combination thereof, will generally have an insignificant effect on the function of the polypeptide.

As used herein, an MLK4-related polypeptide is "useful in practicing the invention" where the polypeptide can be used to raise antibodies against an MLK4 gene product from a eukaryotic, preferably mammalian, and most preferably human cell or tissue, or to screen for compounds that modulate MLK4 activity or production in such a cell or tissue.

The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned MLK4-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of an MLK4-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of the nucleotide sequence of SEQ ID NO:1 or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, of the length of said nucleotide sequence, and that is useful in practicing the invention, as usefulness is defined above for MLK4-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the MLK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human MLK4 gene product of the present invention. A "peptide fragment" of an MLK4-related polypeptide refers to a polypeptide consisting of a sub-sequence of SEQ ID NO:2, which sub-sequence is useful in practicing the invention, as usefulness is defined above for MLK4-related polypeptides. As used herein, a "peptide fragment" is preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

The MLK4-related polynucleotide molecules disclosed herein can be used to express a portion of the human MLK4 gene product, to detect expression of an MLK4 gene product in a cell type or tissue, to prepare novel cell lines in which the MLK4 gene has been mutated (for

example, altered or removed by homologous recombination), to create and express a dominant-negative MLK4, e.g., by mutating the ATP binding site, using well known techniques (see, e.g., Abo et al., below), and to identify MLK4 homolog genes in eukaryotic species other than humans, and particularly in other mammalian species, using known techniques. Thus, the present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding an MLK4 homolog gene product. As used herein, an "MLK4 homolog gene product" is defined as a gene product encoded by an MLK4 homolog gene which, in turn, is defined as a gene from a different eukaryotic species other than human and which is recognized by those of skill in the art as a homolog of the human MLK4 gene based on a degree of sequence identity at the amino acid level of greater than about 70%.

Methods for identifying polynucleotide clones containing MLK4 homolog genes are known in the art. For example, a polynucleotide molecule comprising a portion of the human MLK4 ORF can be detectably labeled and used to screen a genomic library constructed from DNA derived from the organism of interest. The stringency of the hybridization conditions can be selected based on the relationship of the reference organism to the organism of interest. Requirements for different stringency conditions are well known to those of skill in the art, and such conditions will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. Genomic DNA libraries can be screened for MLK4 homolog gene coding sequences using the techniques set forth, among other places, in Benton and Davis, 1977, Science 196:180, for bacteriophage libraries, and in Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. USA, 72:3961-3965, for plasmid libraries, which publications are incorporated herein by reference. Polynucleotide molecules having nucleotide sequences known to include a portion of the MLK4 ORF, as shown in SEQ ID NO:1, or oligonucleotide molecules representing portions thereof, can be used as probes in these screening experiments. Alternatively, oligonucleotide probes can be synthesized that correspond to nucleotide sequences deduced from the amino acid sequence of the purified MLK4 gene product.

Clones identified as containing MLK4 homolog gene coding sequences can be tested for appropriate biological function. For example, the clones can be subjected to sequence analysis in order to identify a suitable reading frame, as well as initiation and termination signals. The cloned DNA sequence can then be inserted into an appropriate expression vector which is then transformed into cells (such as human cells) that have been rendered MLK4 null to test for complementation. Transformed host cells can then be analyzed for MLK4 signal transduction.

5.1.2. PAK4-related Polynucleotide Molecules

The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK4 gene product. In a

preferred embodiment, the portion of the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:3.

5 The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:3. The term "homologous" when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by SEQ ID NO:3, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:3, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK) and hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:4 under moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:4 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1 % SDS at 68°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:3, and is useful in practicing the invention.

25 As used herein, a PAK4-related polynucleotide molecule is "useful in practicing the invention" where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the PAK4 gene product from a eukaryotic cell; or (ii) can detect the presence of the PAK4 transcript in a test sample; or (iii) 30 can enable a method for altering the regulation or expression of the endogenous PAK4 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide sequence of the PAK4 ORF in a eukaryotic cell using standard amplification techniques such as PCR. Such homologous 35 polynucleotide molecules can include naturally occurring PAK4 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example, mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated PAK4

alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:4. As used herein to
5 refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a PAK4 gene product from a human cell, the term "homologous" means a polypeptide comprising the amino acid sequence of SEQ ID NO:4, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, as conservative amino acid substitutions are defined above, wherein the resulting
10 amino acid sequence has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:4, as determined, e.g., using the BLASTP algorithm (GENBANK), where the resulting polypeptide is useful in practicing the invention.

As used herein, a PAK4-related polypeptide is "useful in practicing the invention"
15 where the polypeptide can be used to raise antibodies against a PAK4 gene product from a eukaryotic, preferably mammalian, and most preferably human, cell or tissue, or to screen for compounds that modulate PAK4 activity or production in such a cell or tissue.

The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK4-
20 related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a PAK4-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of SEQ ID NO:3 or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, of the length of said nucleotide sequence, and that is useful in practicing the invention, as
25 usefulness is defined above for PAK4-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the PAK4-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK4 gene product of the present invention. A "peptide fragment" of a PAK4-related polypeptide refers to a polypeptide consisting of a sub-sequence of SEQ ID NO:4, which sub-sequence is useful in
30 practicing the invention, as usefulness is defined above for PAK4-related polypeptides. Peptide fragments of the invention are preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

The PAK4-related polynucleotide molecules disclosed herein can be used to express
35 a portion of the human PAK4 gene product, to detect expression of a PAK4 gene product in a cell type or tissue, to prepare novel cell lines in which the PAK4 gene has been mutated (for example, altered or removed by homologous recombination), to create and express a dominant-negative PAK4, e.g., by mutating the ATP binding site, using well known techniques

(see, e.g., Abo et al., below), and to identify PAK4 homolog genes in eukaryotic species other than humans, and particularly in other mammalian species, using known techniques. Thus, the present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK4 homolog gene product. As used herein, a “PAK4 homolog gene product” is defined as a gene product encoded by a PAK4 homolog gene which, in turn, is defined as a gene from a different eukaryotic species other than human and which is recognized by those of skill in the art as a homolog of the human PAK4 gene based on a degree of sequence identity at the amino acid level of greater than about 70%. Methods for identifying polynucleotide clones containing PAK4 homolog genes are known in the art as described above.

5.1.3. PAK5-related Polynucleotide Molecules

The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a portion of a human PAK5 gene product. In a preferred embodiment, the portion of the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:6 comprises the nucleotide sequence of SEQ ID NO:5. In another preferred embodiment, the portion of the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:8. In a non-limiting embodiment, the isolated polynucleotide molecule encoding the amino acid sequence of SEQ ID NO:8 comprises the nucleotide sequence of SEQ ID NO:7. Still another non-limiting embodiment of the invention is the sequence of any one of the exons of the PAK5 genomic DNA (see SEQ ID NO:7). A further non-limiting embodiment of the invention is the sequence of any one of the introns of the PAK5 genomic DNA.

The present invention further provides an isolated polynucleotide molecule comprising the cDNA nucleotide sequence of SEQ ID NO:9 (ORF from nt 199-2244) encoding a complete human PAK5 gene product. The present invention further provides an isolated polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:11 (ORF from nt 6125-17433), which represents the human PAK5 gene.

The present invention further provides an isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising a nucleotide sequence encoding a portion of a PAK5 gene product of the present invention. The term “homologous” when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 or SEQ ID NO:11, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic code; or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:7, or to the ORF of SEQ

ID NO:9 or SEQ ID NO:11, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK), and hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:10 under
5 moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid
10 sequence of SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:10 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1 % SDS at 68°C (Ausubel et al., 1989, above), and is useful in practicing the invention. In a more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide
15 molecule consisting of the nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:7, or the ORF of SEQ ID NO:9 or SEQ ID NO:11, and is useful in practicing the invention.

As used herein, a PAK5-related polynucleotide molecule is "useful in practicing the invention" where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the PAK5 gene product from a
20 eukaryotic cell; or (ii) can detect the presence of the PAK5 transcript in a test sample; or (iii) can enable a method for altering the regulation or expression of the endogenous PAK5 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide sequence of the PAK5 ORF in a
25 eukaryotic cell using standard amplification techniques such as PCR. Such homologous polynucleotide molecules can include naturally occurring PAK5 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example, mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated PAK5 alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

30 The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10. As used herein to refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a PAK5 gene product from a human cell, the
35 term "homologous" means a polypeptide comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, as conservative

amino acid substitutions are defined above, wherein the resulting amino acid sequence has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, as determined, e.g., using the BLASTP algorithm (GENBANK), and where the resulting polypeptide is useful in practicing the invention.

As used herein, a PAK5-related polypeptide is "useful in practicing the invention" where the polypeptide can be used to raise antibodies against a PAK5 gene product from a eukaryotic, preferably mammalian, and most preferably human, cell or tissue, or to screen for compounds that modulate PAK5 activity or production in such a cell.

The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned PAK5-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a PAK5-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 (from nt 199-2244) or SEQ ID NO:11 (from nt 6125-17433) or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, the length of said nucleotide sequence, and that is useful in practicing the invention, as usefulness is defined above for PAK5-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the PAK5-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a human PAK5 gene product of the present invention. A "peptide fragment" of a PAK5-related polypeptide refers to a polypeptide consisting of a sub-sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, which sub-sequence is useful in practicing the invention, as usefulness is defined above for PAK5-related polypeptides. Peptide fragments of the invention are preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

The PAK5-related polynucleotide molecules disclosed herein can be used to express a portion of the PAK5 gene product, to detect expression of a PAK5 gene in a cell or tissue, to prepare novel cell lines in which the PAK5 gene has been mutated (for example, altered or removed by homologous recombination), to create and express a dominant-negative PAK5 by mutating the ATP binding site using well known techniques (see, e.g., Abo et al., below), and to identify PAK5 homolog genes in other eukaryotic species or cell types using standard techniques. Thus, the present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK5 homolog gene product. As used herein, a "PAK5 homolog gene product" is defined as a gene product encoded by a PAK5 homolog gene which, in turn, is defined as a gene from a eukaryotic species other than human, and which is recognized by those of skill in the art as a homolog of the human PAK5 gene based on a degree of sequence identity at the amino acid level of greater than about 80%. Methods

for identifying polynucleotide clones containing PAK5 homolog genes are known in the art, as described above.

5.1.4. YSK2-related Polynucleotide Molecules

The present invention further provides an isolated polynucleotide molecule
5 comprising a nucleotide sequence encoding a portion of a YSK2 gene product from a human cell. In a preferred embodiment, the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13. In a non-limiting embodiment, the isolated polynucleotide molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:12.

The present invention further provides an isolated polynucleotide molecule that is
10 homologous to a polynucleotide molecule comprising a nucleotide sequence encoding a portion of the YSK2 gene product of the present invention. The term "homologous" when used in this respect means a polynucleotide molecule comprising a nucleotide sequence: (a) that encodes the same polypeptide as encoded by SEQ ID NO:12, but that includes one or more silent changes to the nucleotide sequence according to the degeneracy of the genetic
15 code; or (b) that has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% nucleotide sequence identity to the nucleotide sequence of SEQ ID NO:12, as determined by any standard nucleotide sequence identity algorithm such as BLASTN (GENBANK), and hybridizes to the complement of a polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid
20 sequence of SEQ ID NO:13 under moderately stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, above), and encodes at least the first 6 amino acid residues of SEQ ID NO:13 and is useful in practicing the invention. In a preferred embodiment, the homologous polynucleotide molecule hybridizes to the complement of a
25 polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:13 under highly stringent conditions, i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1 % SDS at 68°C (Ausubel et al., 1989, above), and encodes at least the first 6 amino acid residues of SEQ ID NO:13, and is useful in practicing the invention. In a
30 more preferred embodiment, the homologous polynucleotide molecule hybridizes under highly stringent conditions to the complement of a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:12, and encodes at least the first 6 amino acid residues of SEQ ID NO:13, and is useful in practicing the invention.

As used herein, a YSK2-related polynucleotide molecule is "useful in practicing the
35 invention" where the polynucleotide molecule: (i) encodes a peptide that can be used to generate antibodies that immunospecifically recognize the YSK2 gene product from a eukaryotic cell; or (ii) can detect the presence of the YSK2 transcript in a test sample; or (iii)

can enable a method for altering the regulation or expression of the endogenous YSK2 gene (such as by gene activation or inactivation techniques, e.g., insertion of a transcriptional activator sequence into an intron, or deletion of one or more exons); or (iv) can be used to amplify a polynucleotide molecule comprising the nucleotide sequence of the YSK2 ORF in a eukaryotic cell using standard amplification techniques such as PCR. Such homologous polynucleotide molecules can include naturally occurring YSK2 genes present in eukaryotic species other than humans (and particularly in mammalian species, such as, for example, mouse, cow, sheep, guinea pig and rat), or in other human isolates, as well as mutated YSK2 alleles, whether naturally occurring, chemically synthesized, or genetically engineered.

10 The present invention further provides an isolated polynucleotide molecule comprising a nucleotide sequence that encodes a polypeptide having an amino acid sequence that is homologous to the amino acid sequence of SEQ ID NO:13. As used herein to refer to polypeptides having amino acid sequences that are homologous to the amino acid sequence of a YSK2 gene product from a human cell, the term "homologous" means a polypeptide comprising the amino acid sequence of SEQ ID NO:13, but in which one or more amino acid residues thereof has been conservatively substituted with a different amino acid residue, as conservative amino acid substitutions are defined above, wherein the resulting amino acid sequence has at least about 70%, more preferably at least about 80%, and most preferably at least about 90% sequence identity to SEQ ID NO:13, as determined, e.g., using the BLASTP algorithm (GENBANK), and which encodes at least the first 6 amino acid residues of SEQ ID NO:13 and where the resulting polypeptide is useful in practicing the invention.

As used herein, a YSK2-related polypeptide is "useful in practicing the invention" where the polypeptide can be used to raise antibodies against a YSK2 gene product from a eukaryotic, preferably mammalian, and most preferably human, cell or tissue, or to screen for compounds that modulate YSK2 activity or production in such a cell or tissue.

The present invention further provides an isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of any of the aforementioned YSK2-related polynucleotide molecules of the present invention. As used herein, a "substantial portion" of a YSK2-related polynucleotide molecule means a polynucleotide molecule consisting of less than the full length of SEQ ID NO:12 or homologous polynucleotide molecule thereof, but comprising at least about 20%, and more preferably at least about 30%, the length of said nucleotide sequence, and encoding at least the first 6 amino acid residues of SEQ ID NO:13 and that is useful in practicing the invention, as usefulness is defined above for YSK2-related polynucleotide molecules. In a non-limiting embodiment, the substantial portion of the YSK2-related polynucleotide molecule consists of a nucleotide sequence that encodes a peptide fragment of a YSK2 gene product of the present invention. A "peptide

fragment" of a YSK2-related polypeptide refers to a polypeptide consisting of a sub-sequence of the amino acid sequence of SEQ ID NO:13, yet contains the sequence of residues 1 to 6 of SEQ ID NO:13, and which sub-sequence is useful in practicing the invention, as usefulness is defined above for YSK2-related polypeptides. Peptide fragments of the invention are preferably at least about 15 amino acid residues, and more preferably at least about 30 amino acid residues in length.

The YSK2-related polynucleotide molecules disclosed herein can be used to express a portion of the human YSK2 gene product, to detect expression of a YSK2 gene product in a cell type or tissue, to prepare novel cell lines in which the YSK2 gene has been mutated (for example, altered or removed by homologous recombination), to create and express a dominant-negative YSK2 by mutating the ATP binding site using well known techniques (see, e.g., Abo et al., below), and to identify YSK-2 homolog genes in other eukaryotic species or cell types, as described above. As used herein, a "YSK2 homolog gene product" is defined as a gene product encoded by a YSK2 homolog gene which, in turn, is defined as a gene from a eukaryotic species other than human, and which is recognized by those of skill in the art as a homolog of the human YSK2 gene based on a degree of sequence identity at the amino acid level of greater than about 80%. Methods for identifying polynucleotide clones containing YSK2 homolog genes are known in the art, as described above.

5.2. Oligonucleotide Molecules

The present invention further provides oligonucleotide molecules that hybridize to any of the aforementioned polynucleotide molecules of the present invention, or that hybridize to a polynucleotide molecule having a nucleotide sequence that is the complement of any of the aforementioned polynucleotide molecules of the present invention. Such oligonucleotide molecules are preferably at least about 10 nucleotides in length, and more preferably at least about 20 nucleotides in length, and can hybridize to one or more of the aforementioned polynucleotide molecules under moderately or highly stringent conditions. For shorter oligonucleotide molecules, an example of highly stringent conditions includes washing in 6xSSC/0.5% sodium pyrophosphate at about 37°C for ~14-base oligos, at about 48°C for ~17-base oligos, at about 55°C for ~20-base oligos, and at about 60°C for ~23-base oligos. For longer oligonucleotide molecules (i.e., greater than about 100 nts), examples of moderately and highly stringent conditions are described in Section 5.1.1 above for homologous polynucleotide molecules. Hybridization conditions can be appropriately adjusted as known in the art, depending upon the particular oligonucleotide molecules utilized.

In a preferred embodiment, an oligonucleotide molecule of the present invention hybridizes under highly stringent conditions to a polynucleotide molecule having a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11 or 12, or to a

polynucleotide molecule having a nucleotide sequence that is the complement of a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11 or 12.

5 The oligonucleotide molecules of the present invention are useful for a variety of purposes, including as primers in amplifying a MLK4, PAK4, PAK5 or YSK2 gene product-encoding polynucleotide molecule, or as anti-sense molecules useful in regulating expression of JNKKK genes and gene products. Amplification can be carried out using suitably designed oligonucleotide molecules in conjunction with standard techniques, such as the polymerase chain reaction (PCR), although other amplification techniques known in the art, e.g., the ligase chain reaction, can also be used. For example, for PCR, a mixture comprising suitably
10 designed primers, a template comprising the nucleotide sequence to be amplified, and appropriate PCR enzymes and buffers, is prepared and processed according to standard protocols to amplify a specific MLK4-, PAK4-, PAK5-, or YSK2-related polynucleotide sequence of the template.

15 **5.3. Recombinant Expression Systems**

5.3.1. Expression Vectors

The present invention further provides recombinant cloning vectors and recombinant expression vectors comprising a polynucleotide molecule of the present invention, which vectors are useful in cloning or expressing said polynucleotide molecules, including polynucleotide molecules comprising portions of the MLK4, PAK4, PAK5 or YSK2 ORFs, or
20 the entire PAK5 ORF, of the present invention.

The following description is intended to apply to all of the aforementioned polynucleotide molecules and polypeptides of the present invention, including polynucleotide molecules comprising portions of the MLK4, PAK4, PAK5 or YSK2 ORFs, the entire PAK5 ORF, and their gene products, and all homologous polynucleotide molecules, homologous
25 polypeptides, substantial portions of such polynucleotide molecules, and peptide fragments of such gene products and polypeptides, as defined above, unless otherwise indicated.

Recombinant vectors of the present invention, particularly expression vectors, are preferably constructed so that the coding sequence for the polynucleotide molecule of the present invention is in operative association with one or more regulatory elements necessary
30 for transcription and translation of the coding sequence to produce a polypeptide. As used herein, the term "regulatory element" includes but is not limited to nucleotide sequences of inducible and noninducible promoters, enhancers, operators and other elements known in the art that serve to drive and/or regulate expression of polynucleotide coding sequences. Also, as used herein, the coding sequence is in "operative association" with one or more regulatory
35 elements where the regulatory elements effectively regulate and allow for the transcription of the coding sequence or the translation of its mRNA, or both.

Typical plasmid vectors that can be engineered to contain a polynucleotide molecule

of the present invention include pCR-Blunt, pCR2.1 (Invitrogen), and pGEM3Zf (Promega), among many others. Additionally, vectors particularly designed for expression in eukaryotic cells, such as mammalian cells, are commercially available from Invitrogen (San Diego, CA) and Promega.

5 The regulatory elements of these vectors can vary in their strength and specificities. Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements can be used. Non-limiting examples of transcriptional regulatory regions or promoters for bacteria include the β -gal promoter, the T7 promoter, the TAC promoter, lambda left and right promoters, trp and lac promoters, and the trp-lac fusion promoters. Non-
10 limiting examples of transcriptional regulatory regions or promoters for eukaryotic cells include viral regulatory regions such as, for example, the SV40 early promoter region, the herpes thymidine kinase promoter, the cytomegalovirus (CMV) promoter, and the mouse mammary tumor virus control region, tissue specific or inducible promoters from endogenous eukaryotic genes such as, for example, the albumin promoter, myosin light chain-2 promoter, the insulin
15 promoter, the metallothionein promoter, and fungal promoters such as, for example, the gal 4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, and the mating factor promoters, to name just a few.

 Methods are well-known in the art for constructing recombinant vectors containing particular coding sequences in operative association with appropriate regulatory elements, and any of these can be used to practice the present invention. These methods include in
20 vitro recombinant techniques, synthetic techniques, and in vivo genetic recombination. See, e.g., the techniques described in Maniatis et al., 1989, above; Ausubel et al., 1989, above; Sambrook et al., 1989, above; Innis et al., 1995, above; and Erlich, 1992, above.

 Fusion protein expression vectors can be used to express an MLK4, PAK4, PAK5 or
25 YSK2 gene product-fusion protein. The purified fusion protein can be used to raise antisera against the MLK4, PAK4, PAK5 or YSK2 gene product, to study the biochemical properties of the MLK4, PAK4, PAK5 or YSK2 gene product, to engineer the MLK4, PAK4, PAK5 or YSK2 fusion proteins with different biochemical activities, or to aid in the identification or purification of the expressed MLK4, PAK4, PAK5 or YSK2 gene product in recombinant expression
30 systems. Possible fusion protein expression vectors include but are not limited to vectors incorporating sequences that encode β -galactosidase and trpE fusions, maltose binding protein fusions, glutathione-S-transferase fusions and polyhistidine fusions (carrier regions).

 MLK4, PAK4, PAK5 or YSK2 fusion proteins can be engineered to comprise a region useful for purification. For example, MLK4-, PAK4-, PAK5- and YSK2-maltose-binding protein
35 fusions can be purified using amylose resin; MLK4-, PAK4-, PAK5- and YSK2-glutathione-S-transferase fusion proteins can be purified using glutathione-agarose beads; and MLK4-, PAK4-, PAK5- and YSK2-polyhistidine fusions can be purified using divalent nickel resin.

Alternatively, antibodies against a carrier protein or peptide can be used for affinity chromatography purification of the fusion protein. For example, a nucleotide sequence coding for the target epitope of a monoclonal antibody can be engineered into the expression vector in operative association with the regulatory elements and situated so that the expressed epitope is fused to the MLK4, PAK4, PAK5 or YSK2 polypeptide. For example, a nucleotide sequence coding for the FLAG™ epitope tag (International Biotechnologies Inc.), which is a hydrophilic marker peptide, can be inserted by standard techniques into the expression vector at a point corresponding to the amino or carboxyl terminus of the MLK4, PAK4, PAK5 or YSK2 polypeptide. The expressed MLK4, PAK4, PAK5 or YSK2 polypeptide-FLAG™ epitope fusion product can then be detected and affinity-purified using commercially available anti-FLAG™ antibodies.

The expression vector encoding the MLK4, PAK4, PAK5 or YSK2 fusion protein can also be engineered to contain sequences that encode specific protease cleavage sites so that the expressed MLK4, PAK4, PAK5 or YSK2 polypeptide can be released from the carrier region or fusion partner by treatment with a specific protease. For example, the fusion protein vector can include DNA sequences encoding thrombin or factor Xa cleavage sites, among others.

A signal sequence upstream from and in reading frame with the MLK4, PAK4, PAK5 or YSK2 ORF can be engineered into the expression vector by known methods to direct the trafficking and secretion of the expressed gene product. Non-limiting examples of signal sequences include those from α factor, immunoglobulins, outer membrane proteins, penicillinase, and T-cell receptors, among others.

To aid in the selection of host cells transformed or transfected with cloning or expression vectors of the present invention, the vector can be engineered to further comprise a coding sequence for a reporter gene product or other selectable marker. Such a coding sequence is preferably in operative association with regulatory element coding sequences, as described above. Reporter genes that can be useful in the invention are well known in the art and include those encoding green fluorescent protein, luciferase, xylE, and tyrosinase, among others. Nucleotide sequences encoding selectable markers are well known in the art, and include those that encode gene products conferring resistance to antibiotics or anti-metabolites, or that supply an auxotrophic requirement. Examples of such sequences include those that encode resistance to methotrexate, G418 or mycophenolic acid, among many others.

5.3.2. Host Cells

The present invention further provides transformed host cells comprising a polynucleotide molecule or recombinant vector of the invention, and novel strains or cell lines derived therefrom. Host cells useful in the practice of the invention are preferably human

cells, although other eukaryotic cells or prokaryotic cells can also be used. Such other transformed host cells typically include but are not limited to microorganisms, such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA vectors, or yeast transformed with recombinant vectors, among others.

5 Appropriate host cells can be chosen that modify and process the gene product in the specific fashion desired. Different host cells have characteristic mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation) of proteins. For example, expression in a bacterial system can be used to produce an unglycosylated protein product. Expression and secretion in yeast can produce a
10 glycosylated protein product. Expression in mammalian cells can be used to ensure "native" processing of a protein product. Further, different vector/host expression systems can affect processing reactions to different degrees.

 Preferred bacterial cells as host cells are strains of *E. coli*, e.g., for cloning or expression purposes. A strain of *E. coli* adapted to growth in culture and for cloning
15 techniques can typically be used, such as, e.g., the DH5 α strain, which is available either from the American Type Culture Collection (ATCC), Rockville, MD, USA (Accession No. 31343) or from commercial sources (Stratagene). Preferred eukaryotic host cells include human cells, and in particular keratinocytes, although other mammalian cells and yeast cells or insect cells can also be utilized effectively.

20 The recombinant expression vector of the invention is preferably transformed or transfected into one or more host cells of a substantially homogeneous culture of cells. The expression vector is generally introduced into host cells in accordance with known techniques, such as, e.g., by protoplast transformation, calcium phosphate precipitation, calcium chloride treatment, microinjection, electroporation, transfection by contact with a
25 recombined virus, liposome-mediated transfection, DEAE-dextran transfection, transduction, conjugation, or microprojectile bombardment. Selection of transformants can be conducted by standard procedures, such as by selecting for cells expressing a selectable marker, e.g., antibiotic resistance, associated with the recombinant vector, as described above.

 Once the expression vector is introduced into the host cell, the integration and
30 maintenance of the MLK4-, PAK4-, PAK5- or YSK2-related coding sequence, either in the host cell chromosome or episomally, can be confirmed by standard techniques, e.g., by Southern hybridization analysis, restriction enzyme analysis, PCR analysis, including reverse transcriptase PCR (rt-PCR), or by immunological assay to detect the expected gene product. Host cells containing and/or expressing the recombinant MLK4-, PAK4-, PAK5- or YSK2-
35 related coding sequence can be identified by any of at least four general approaches which are well-known in the art, including: (i) DNA-DNA, DNA-RNA, or RNA-antisense RNA hybridization; (ii) detecting the presence of "marker" gene functions; (iii) assessing the level of

transcription as measured by the expression of MLK4-, PAK4-, PAK5- or YSK2-specific mRNA transcripts in the host cell; and (iv) detecting the presence of mature polypeptide product as measured, e.g., by immunoassay.

5.3.3. Expression And Characterization Of JNKKK Polypeptides

5 Once the MLK4-, PAK4-, PAK5- or YSK2-related coding sequence has been stably introduced into an appropriate host cell, the transformed host cell is clonally propagated, and the resulting cells are grown under conditions conducive to the maximum production of the MLK4-, PAK4-, PAK5- or YSK2-related gene products. Such conditions typically include growing cells to high density. Where the expression vector comprises an inducible promoter, 10 appropriate induction conditions such as, e.g., temperature shift, exhaustion of nutrients, addition of gratuitous inducers (e.g., analogs of carbohydrates, such as isopropyl- β -D—thiogalactopyranoside (IPTG)), accumulation of excess metabolic by-products, or the like, are employed as needed to induce expression.

 Where the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene product is 15 retained inside the host cells, the cells are harvested and lysed, and the product is isolated and purified from the lysate under extraction conditions known in the art to minimize protein degradation such as, e.g., at 4°C, or in the presence of protease inhibitors, or both. Where the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene product is secreted from the host cells, the exhausted nutrient medium can simply be collected and the product isolated 20 therefrom.

 The expressed MLK4-, PAK4-, PAK5- or YSK2-related gene product can be isolated or substantially purified from cell lysates or culture medium, as appropriate, using standard methods, including but not limited to any combination of the following methods: ammonium sulfate precipitation, size fractionation, ion exchange chromatography, HPLC, density 25 centrifugation, and affinity chromatography. Where the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene products exhibit biological activity, increasing purity of the preparation can be monitored at each step of the purification procedure by use of an appropriate assay. Whether or not the expressed MLK4-, PAK4-, PAK5- or YSK2-related gene products exhibit biological activity, each can be detected as based, e.g., on size, or reactivity with an antibody 30 otherwise specific for MLK4, PAK4, PAK5 or YSK2, or by the presence of a fusion tag.

 The present invention thus provides a substantially purified or isolated polypeptide encoded by a polynucleotide molecule of the present invention. In a specific though non-limiting embodiment, the polypeptide is a human MLK4 gene product, or a portion thereof, comprising the amino acid sequence of SEQ ID NO:2. In another specific though non-limiting 35 embodiment, the polypeptide is a human PAK4 gene product, or a portion thereof, comprising the amino acid sequence of SEQ ID NO:4. In still another specific though non-limiting embodiment, the polypeptide is a human PAK5 gene product, or a portion thereof, comprising

the amino acid sequence of SEQ ID NO:6, 8 or 10. In another specific though non-limiting embodiment, the polypeptide is a human YSK-2 gene product, or a portion thereof, comprising the amino acid sequence of SEQ ID NO:13. The present invention further provides substantially purified or isolated polypeptides that are homologous to any of the MLK4, PAK4, PAK5 or YSK2 gene products of the present invention, as homologous polypeptides are defined above. The present invention further provides peptide fragments of the MLK4, PAK4, PAK5 or YSK2 gene products or homologous polypeptides of the present invention, as peptide fragments are defined above. The substantially purified or isolated polypeptides of the present invention are useful for a variety of purposes, such as, e.g., screening for compounds that interact with MLK4, PAK4, PAK5 or YSK2 proteins, and hence are candidates for compounds that affect MLK4, PAK4, PAK5 or YSK2 activity (including the events involved in signal transduction), and for raising antibodies directed against MLK4, PAK4, PAK5 or YSK2 gene product. Such compounds and antibodies can be used in therapeutic methods to treat or prevent UV damage to the skin.

As used herein, a polypeptide is "substantially purified" where the polypeptide constitutes the majority (i.e., at least about 50%) by weight of the material in a particular preparation. Also, as used herein, a polypeptide is "isolated" where the polypeptide constitutes at least about 90 wt% of the material in a particular preparation. Also, as used herein, a polynucleotide molecule is "isolated" where it constitutes at least about 90 wt% of the nucleic acid material in a particular preparation, or where it appears to be separated from all other polynucleotide molecules as determined, e.g., by gel electrophoresis techniques.

The present invention further provides a method of preparing a substantially purified or isolated MLK4 gene product, PAK4 gene product, PAK5 gene product, YSK2 gene product or peptide fragment of the present invention, comprising culturing a host cell transformed or transfected with a polynucleotide molecule or recombinant vector of the present invention, said recombinant vector comprising a polynucleotide molecule comprising a nucleotide sequence encoding the MLK4 gene product, PAK4 gene product, PAK5 gene product, YSK2 gene product or peptide fragment, respectively, of the present invention, wherein the nucleotide sequence is in operative association with one or more regulatory elements, under conditions conducive to the expression of the particular gene product, polypeptide, or peptide fragment, and recovering the expressed gene product, polypeptide, or peptide fragment, from the cell culture in a substantially purified or isolated form.

Once an MLK4, PAK4, PAK5 or YSK2 gene product of sufficient purity has been obtained, it can be characterized by standard methods, including by SDS-PAGE, size exclusion chromatography, amino acid sequence analysis, biological activity such as kinase activity, etc. For example, the amino acid sequence of the MLK4, PAK4, PAK5 or YSK2 gene product can be determined using standard peptide sequencing techniques. The MLK4,

PAK4, PAK5 or YSK2 gene product can be further characterized using hydrophilicity analysis (see, e.g., Hopp and Woods, 1981, Proc. Natl. Acad. Sci. USA 78:3824), or analogous software algorithms, to identify hydrophobic and hydrophilic regions of the MLK4, PAK4, PAK5 or YSK2 gene product respectively. Structural analysis can be carried out to identify regions of the MLK4, PAK4, PAK5 or YSK2 gene product that assume specific secondary structures. Biophysical methods such as X-ray crystallography (Engstrom, 1974, Biochem. Exp. Biol. 11:7-13), computer modeling (Eletterick and Zoller (eds), 1986, in: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), and nuclear magnetic resonance (NMR) can be used to map and study sites of interaction between the MLK4, PAK4, PAK5 or YSK2 gene products and their substrates. Information obtained from these studies can be used to select specific sites on the MLK4, PAK4, PAK5 or YSK2 gene products as potential targets for drug candidates that interact with, and alter the activity of, these gene products.

5.4. Antibodies

The present invention further provides polyclonal and monoclonal antibodies that bind to an MLK4 gene product, PAK4 gene product, PAK5 gene product, YSK2 gene product, or to an homologous polypeptide or peptide fragment, of the present invention. Such antibodies can be used as affinity reagents with which to purify a native MLK4, PAK4, PAK5 or YSK2 gene product, or to analyze the activity or biological function of the MLK4, PAK4, PAK5 or YSK2 gene product.

Antibodies can be raised against any of the MLK4-, PAK4-, PAK5- or YSK2-related polypeptides of the present invention. Various host animals, including but not limited to cows, horses, rabbits, goats, sheep, and mice, can be used according to known methods to produce anti-MLK4, anti-PAK4, anti-PAK5 or anti-YSK2-specific antibodies. Various adjuvants known in the art can be used to enhance antibody production.

Polyclonal antibodies can be obtained from immunized animals and tested for anti-MLK4, anti-PAK4, anti-PAK5 or anti-YSK2 specificity using standard techniques. Alternatively, monoclonal antibodies to an MLK4, PAK4, PAK5 or YSK2 polypeptide can be prepared using any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein (Nature, 1975, 256: 495-497); the human B-cell hybridoma technique (Kosbor, et al., 1983, Immunology Today 4:72; Cote, et al., 1983, Proc. Natl. Acad. Sci. USA 80: 2026-2030); and the EBV-hybridoma technique (Cole, et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77- 96). Alternatively, techniques described for the production of single chain antibodies (see, e.g., U.S. Patent 4,946,778) can be adapted to produce MLK4-, PAK4-, PAK5- or YSK2- specific single chain antibodies. These publications are incorporated herein by reference.

Antibody fragments that contain specific binding sites for an MLK4, PAK4, PAK5 or YSK2 polypeptide are also encompassed within the present invention and can be generated by known techniques. Such fragments include but are not limited to F(ab')₂ fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries can be constructed (Huse *et al.*, 1989, Science 246: 1275-1281) to allow rapid identification of Fab fragments having the desired specificity to the MLK4, PAK4, PAK5 or YSK2 polypeptide.

Techniques for the production of monoclonal antibodies and antibody fragments are well-known in the art, and are additionally described, among other places, in Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory; and in J. W. Goding, 1986, Monoclonal Antibodies: Principles and Practice, Academic Press, London. All of the above-cited publications are incorporated herein by reference.

5.5. Anti-sense Oligonucleotides And Ribozymes

Also within the scope of the present invention are oligonucleotide sequences that include anti-sense oligonucleotides, phosphorothioates and ribozymes that function to bind to, degrade and/or inhibit the translation of MLK4, PAK4, PAK5 or YSK2 mRNA.

Anti-sense oligonucleotides, including anti-sense RNA molecules and anti-sense DNA molecules, act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. For example, antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the DNA sequence encoding an MLK4, PAK4, PAK5 or YSK2 polypeptide can be synthesized, e.g., by conventional phosphodiester techniques.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of MLK4, PAK4, PAK5 or YSK2 mRNA sequences are also within the scope of the present invention.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites that include the following sequences, GUA, GUU, and GUC. Once identified, short RNA sequences of between about 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides using, e.g., ribonuclease protection assays.

Both the anti-sense oligonucleotides and ribozymes of the present invention can be prepared by known methods. These include techniques for chemical synthesis such as, e.g., by solid phase phosphoamite chemical synthesis. Alternatively, anti-sense RNA molecules can be generated by in vitro or in vivo transcription of DNA sequences encoding the RNA molecule. Such DNA sequences can be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters.

Various modifications to the oligonucleotides of the present invention can be introduced as a means of increasing intracellular stability and half-life. Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2'-O-methyl rather than phosphodiesterase linkages within the oligonucleotide backbone.

5.6. Detection Of JNKKK Gene Products, And Diagnostic And Therapeutic Uses

The MLK4, PAK4, PAK5 and YSK2 polynucleotide molecules, oligonucleotides, and polypeptides of the present invention, as well as antibodies of the present invention that recognize the MLK4, PAK4, PAK5 or YSK2 polypeptides, are useful in the diagnosis of diseases or conditions resulting from alteration in the expression of MLK4, PAK4, PAK5 or YSK2 gene products. Alteration in expression can be either an increase or decrease in transcription of the MLK4, PAK4, PAK5 or YSK2 gene, or an increase or decrease in translation of an MLK4, PAK4, PAK5 or YSK2 gene product. Alternatively, the presence of mutations, alleles, or polymorphisms in the MLK4, PAK4, PAK5 or YSK2 gene sequence can be correlated with diseases or conditions, including but not limited to increased or decreased susceptibility to skin damage caused by ultraviolet light or other stresses, or psoriasis.

Nucleic acid-based detection methods are well known in the art and include hybridization assays (e.g., Northern and Southern hybridizations, nuclease protection), polymerase chain reaction (PCR) assays, and ligation chain reaction (LCR) assays, or combinations of the above (e.g., in situ hybridization). Such assays make use of the MLK4, PAK4, PAK5 or YSK2 polynucleotides and oligonucleotides of the present invention, including complementary sequences, as described above. If analysis of an RNA gene product is desired, certain assays would typically include a reverse transcription step prior to amplification and/or hybridization, as known in the art. Such nucleic acid based techniques can be designed by those of ordinary skill in the art to assay the levels of MLK4, PAK4, PAK5 or YSK2 gene expression, or the presence or absence of particular mutations, alleles or polymorphisms.

Protein or polypeptide-based detection methods are also well known to those of ordinary skill and include, e.g., immunological assays such as Western blot, immunoprecipitation of labeled target, and ELISA assays. These assays use the antibodies

of the present invention described above. Again, such assays can measure levels of MLK4, PAK4, PAK5 or YSK2 polypeptides expressed by a cell or organism, or the presence of mutants, alleles, or polymorphisms in the MLK4, PAK4, PAK5 or YSK2 polypeptides.

If an abnormal condition is associated with the over- or under-production of an MLK4, PAK4, PAK5 or YSK2 gene product, the polynucleotides and oligonucleotides of the invention can be useful in preventing, ameliorating or otherwise treating of the abnormal condition. For example, by introducing gene sequences into cells, gene therapy can be used to treat conditions in which the cells express inadequate levels of MLK4, PAK4, PAK5 or YSK2 gene product, or express abnormal or inactive MLK4, PAK4, PAK5 or YSK2 polypeptides. In some instances, abnormal conditions characterized by over-expression of MLK4, PAK4, PAK5 or YSK2 gene product can be prevented or treated using the gene therapy techniques described below. Specifically, gene therapy vectors can be designed to express anti-sense polynucleotides or ribozymes of the present invention as described above, thereby reducing the amount of MLK4, PAK4, PAK5 or YSK2 gene products that are effectively translated into polypeptide.

Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or papilloma virus can be used for delivery of recombinant MLK4, PAK4, PAK5 or YSK2 polynucleotides into the targeted cell population. Methods that are well known to those skilled in the art can be used to construct recombinant viral vectors containing an MLK4, PAK4, PAK5 or YSK2 polynucleotide. See, for example, the techniques described in Maniatis et al., 1989, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y.; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, N.Y. Alternatively, recombinant, non-viral vectors containing an MLK4, PAK4, PAK5 or YSK2 polynucleotide can be reconstituted into liposomes for delivery to target cells, or can be delivered as a naked polynucleotide, such as, e.g., in a "DNA Vaccine," to name just a few examples.

5.7. Drug Screening Applications

MLK4, PAK4, PAK5 and YSK2 gene products, including polynucleotides, oligonucleotides and polypeptides, can be used in screening assays to identify compounds that specifically bind to MLK4, PAK4, PAK5 or YSK2 gene products and thus have potential use as agonists or antagonists of MLK4, PAK4, PAK5 or YSK2 polypeptides, respectively. In a particular preferred use, the polynucleotides and polypeptides of the invention are useful to screen for compounds that affect the kinase activities of MLK4, PAK4, PAK5 or YSK2 polypeptides.

The invention thus provides assays to detect molecules that specifically bind to MLK4, PAK4, PAK5 or YSK2 polypeptides. For example, recombinant cells expressing an MLK4, PAK4, PAK5 or YSK2 polynucleotide can be used to recombinantly produce an MLK4,

PAK4, PAK5 or YSK2 polypeptide, respectively, and to screen for molecules that bind to an MLK4, PAK4, PAK5 or YSK2 polypeptide, respectively. Methods that can be used to carry out the foregoing are commonly known in the art.

5 Diversity libraries, such as random or combinatorial peptide or non-peptide libraries can be screened for molecules that specifically bind to an MLK4, PAK4, PAK5 or YSK2 polypeptide. Many libraries are known in the art that can be used such as, e.g., chemically synthesized libraries, recombinant (e.g., phage display) libraries, and in vitro translation-based libraries.

10 Examples of chemically synthesized libraries are described in Fodor et al., 1991, Science 251:767-773; Houghten et al., 1991, Nature 354:84-86; Lam et al., 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop et al., 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten et al., 1992, Biotechniques 13:412; Jayawickreme et al., 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; 15 Salmon et al., 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT Publication No. WO 93/20242, dated October 14, 1993; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

20 Examples of phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, R.B. et al., 1992, J. Mol. Biol. 227:711-718; Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318, dated August 18, 1994.

In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058, dated April 18, 1991; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

25 In one example, non-peptide libraries, such as a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712), can be screened. Peptoid libraries, such as that described by Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371, can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed 30 combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

35 Screening the libraries can be accomplished by any of a variety of commonly known methods. See, for example, the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992, BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al., 1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992,

Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850- 852; U.S. Patent No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and PCT Publication No. WO 94/18318.

5 In a specific embodiment, screening can be carried out by contacting the library members with an MLK4, PAK4, PAK5 or YSK2 polypeptide immobilized on a solid phase and harvesting those library members that bind to the polypeptide. Examples of such screening methods, termed "panning" techniques, are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422- 427; PCT
10 Publication No. WO 94/18318; and in other references cited hereinabove.

In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to an MLK4, PAK4, PAK5 or YSK2 polypeptide within a cell.

15 In another aspect of the invention, methods for screening candidate compounds for drugs are provided. Such drugs can be used to reduce ultraviolet light-induced damage, inflammation and psoriasis, and enhance wound healing in a subject. The subject is an animal, typically a mammal, preferably a human.

For example, one can screen for compounds that affect the expression of an MLK4,
20 PAK4, PAK5 or YSK2 gene product of the present invention by: (a) applying a test compound to a test sample; (b) determining the expression of at least one MLK4, PAK4, PAK5 or YSK2 gene product in the test sample; and (c) comparing the expression of the gene in the test sample with that in a reference sample. A specific change in the cellular level of the gene product in the test sample as compared to the reference sample indicates that the compound
25 affects the cellular level of gene product from a JNKKK gene. By the term "a specific change in the cellular level of the gene product" is meant that the change in level occurs without alteration of overall transcription or translation levels in the cell (depending upon the gene product assayed). For example, when mRNA is measured, a compound that causes a "specific change" is not a compound that is a general transcriptional repressor. Similarly, for
30 example, when protein levels are assayed, a compound that causes a "specific change" is not a general translational repressor. One can determine whether global effects on transcription or translation occur in the presence of a test compound by assaying for a control housekeeping gene product (e.g., glucose-6- phosphate dehydrogenase gene product or the actin gene product, to name just two examples).

35 One can also assay the effect of a test compound on the expression or cellular response of the MLK4, PAK4, PAK5 or YSK2 gene or polypeptide in the presence of, or in response to, a stress event. The stress event applied to the cells can be exposure to

ultraviolet radiation. Preferred ultraviolet radiation can be UV-A with a wavelength in the range of 320-400 nm, or UV-B with a wavelength in the range of 280-320 nm, or UV-C with a wavelength in the range of 200-280 nm. Other types of stress events applied to the sample for screening purposes can be exposure to inflammatory cytokines such as TNF- α , IL-1, interferons, FGFs or PDGF. Still other types of stress events are heat shock, osmotic shock, exposure to toxic chemicals such as arsenic, disruption of the permeability barrier (e.g., with solvents), etc.

In one preferred embodiment, the method of drug screening comprises: (a) applying a test compound to a test sample; (b) exposing the test sample and a reference sample to a stress event; (c) determining the expression of at least one gene product in the test sample, wherein the transcript of the gene product comprises a sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11 and 12; and (d) determining the effectiveness of the test compound in blocking or otherwise modulating the cellular response to the stress event by comparing the expression of the gene product in the test sample with that in the reference sample. If the test compound significantly reduces the expression of the transcript in response to the stress event, the test compound is identified as a drug candidate that may be potentially effective in blocking the cellular response to the stress event. The expression of the MLK4, PAK4, PAK5 or YSK2 gene product can be determined using any of the methods described above. The most preferred gene products for use in this assay are the PAK5 and YSK2 gene products.

In another preferred embodiment, the method of drug screening entails: (a) applying a test compound to a test sample; (b) applying a stress event to the test sample; and (c) determining the amount of an MLK4, PAK4, PAK5 or YSK2 polypeptide in the test sample and in a reference sample, wherein the MLK4, PAK4, PAK5 or YSK2 polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NOS: 2, 4, 6, 8, 10 and 13; wherein a reduction in the amount of the MLK4, PAK4, PAK5 or YSK2 polypeptide in the test sample as compared to that in the reference sample indicates that the test compound is identified as a drug candidate that can potentially block the stress response.

Still another aspect of the invention is a method of screening for compounds that affect the activity of an MLK4, PAK4, PAK5 or YSK2 polypeptide. One can apply a test compound to a test sample and determine the activity of the MLK4, PAK4, PAK5 or YSK2 polypeptide in the test sample compared to that in a reference sample. A test compound that alters the MLK4, PAK4, PAK5 or YSK2 polypeptide activity in the test sample as compared to the reference sample is identified as a drug candidate that can potentially affect the activity of the MLK4, PAK4, PAK5 or YSK2 polypeptide. Each of the full-length MLK4, PAK4, PAK5 and YSK2 polypeptides is a kinase; thus, the activities of these polypeptides include kinase activity and binding to ATP and its analogs. Other activities include the ability to interact with

activators that activate MLK4, PAK4, PAK5 or YSK2 polypeptide kinase activity, interaction with downstream target proteins, and interaction with inhibitors via the amino-terminal regulatory domain.

5 In another preferred embodiment, the activity of MLK4, PAK4, PAK5 or YSK2 polypeptides, such as kinase activity, binding to ATP and its analogs, or activation of downstream target protein, can be assayed in the test and reference samples in response to application of a stress event, and compared, to predict the effectiveness of the drug candidate. If the drug candidate prevents the induction of the function of the MLK4, PAK4, PAK5 or YSK2 polypeptide by a particular stress event, such as ultraviolet radiation, the drug
10 candidate can be effective at blocking the stress response.

In some preferred embodiments, the test and reference samples are cultured cells, tissues or organs. In other preferred embodiments, the test and reference samples are live animals. In a particularly preferred embodiment, a small biopsy of human skin (e.g., about 5 mm³) is placed in culture and treated with, e.g., ultraviolet radiation, one or more growth
15 factors, cytokines, drugs, hormones or vitamins. After a defined period of time (typically 24-48 hours when the treatment is ultraviolet radiation), the biopsy is tested for expression of the MLK4, PAK4, PAK5 or YSK2 gene product, or for activity of the MLK4, PAK4, PAK5 or YSK2 polypeptide.

The invention having been described, the following examples are offered by way of
20 illustration and not limitation.

6. Example: Cloning Of The YSK2, MLK4, PAK4 And PAK5 cDNAs

This example illustrates the methods used to clone the novel JNKKKs of the invention.

6.1. Materials And Methods

25 Normal human foreskin epidermal keratinocytes were a generous gift from Dr. M. Simon of the State University of New York at Stony Brook. The cultures were initiated using 3T3 feeder layers and then frozen in liquid nitrogen until used. Once thawed, the keratinocytes were grown without feeder cells in defined serum-free keratinocyte growth medium (KGM), supplemented with bovine pituitary extract epidermal growth factor, insulin,
30 thyroid hormone and hydrocortisone (keratinocyte-SFM, GIBCO).

Messenger RNA from the keratinocytes was used for reverse transcription polymerase chain reaction (RT-PCR) amplification with an RT-PCR kit (Promega Corp., Madison, Wisconsin). Primers corresponding to regions of homology between the kinase domains of JNKs or JNKKKs were designed to amplify a 150 bp PCR products from
35 keratinocyte mRNA using RT-PCR. The primers contain the following sequences that correspond to the regions of the kinase domain.

Forward: 5'-ATGCA(CA)CANGA(CT)AT(ACT)AA(AG)-3' (SEQ ID NO:14)

Reverse: 5'-GCNAC(CT)TCNGGNGCCATCCA-3' (SEQ ID NO:15)

The actual primers used for RT-PCR also contained cloning sites. Their sequences are as follows:

Forward: 5'-CCCGAATTCATGCA(CA)CANGA(CT)AT(ACT)AA(AG)-3'
(SEQ ID NO:16)

Reverse: 5'-CCCGAATTCGCNAC(CT)TCNGGNGCCATCCA-3'
(SEQ ID NO: 17)

The PCR products were sub-cloned and sequenced.

6.2. Results

Among the seventy different clones sequenced, ten different JNKKKs were identified, four of which appeared to be novel. An amino acid sequence comparison against the protein databases in the European Molecular Biology Network (available at HYPERLINK <http://www.expasy.ch>; <http://www.expasy.ch>; <http://www.ch.embnet.org>) with other JNKKKs revealed that the four novel JNKKKs exhibited some degree of homology to various known JNKKKs from several different families. One JNKKK clone was 91% identical at positions 12-131 to a 134 base region of the murine YSK2 gene sequence (corresponding to positions 503-384 of emb: U49949, Osada et al., 1997, Oncogene 14:2047-2057); hence, this clone was designated as the human keratinocyte YSK2 (SEQ ID NO:12). Additionally, two human expressed sequence tags (ESTs) were related to the human keratinocyte YSK2. Specifically, Human EST emb:AA557573 (NCI-CGAP, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index <http://www.ncbi.nlm.nih.gov/ncicgap>," Unpublished.) showed a 96% identity with the human YSK2 gene sequence (SEQ ID NO:12) in a 137 bp region corresponding to positions 6-142 of SEQ ID NO:12 and positions 32-168 of emb:AA557573. Human EST emb:AA578088 (NCI-CGAP, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index <http://www.ncbi.nlm.nih.gov/ncicgap>," Unpublished.) also showed a 96% identity with the SEQ ID NO:12 in a 136 bp region corresponding to positions 6-141 of SEQ ID NO:12 and positions 35-170 of emb:AA578088.

Another JNKKK clone, designated MLK4 (SEQ ID NO:1), was 50% to 78% identical to members of the MLK family of JNKKKs. Finally, two JNKKK clones, designated PAK4 (SEQ ID NO:3) and PAK5 (SEQ ID NO:5), showed similar identity to members of the PAK family of JNKKKs. However, no homolog sequences could be found in the European Molecular Biology Network protein database for either MLK4 or PAK5. Although initial sequence searches of PAK4 indicated it was a new member of the PAK gene family, during the course of this work, the complete sequence of human PAK4 was published (Abo et al., 1998, EMBO J 22:6527-6540).

The relative abundance of the different identified JNKKKs is shown below in TABLE 1 below.

Table 1
ABUNDANCE OF DIFFERENT JNKKKs

Kinase	Number of Isolates
BPAG1*	1
GCK	3
LIMK	1
MEKK3	4
MLK4	2
NiK	94
PAK1	40
PAK2	31
PAK4	69
PAK5	59
YSK1	1
Ysk2	51
Total	356

*LIMK is a protein kinase, related to, but not a member of, the JNKKK family. Frangiskakis et al., 1996, Cell 86:59-69. BPAG1 is an abundant protein in basal keratinocytes. Its mRNA contains two segments recognized by the 8 bases at the 3' termini of our oligonucleotides.

The RT-PCR products (SEQ ID NOS:1, 3, 5, 12) of the MLK4, PAK4, PAK5 and YSK2 mRNAs were used as probes for Northern Hybridization to mRNAs from heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Figure 2 shows that the expression of the PAK4 gene is ubiquitous among the organs tested. However, the PAK5 gene is strongly expressed in keratinocytes and in the brain, but not expressed, or only weakly expressed, in placenta, lung, liver, skeletal muscle, kidney and pancreas. The MLK4 gene is expressed in keratinocytes, kidney and pancreas, but not in the brain, placenta, lung, liver, and skeletal muscle. The size of the transcripts of PAK4, PAK5 and MLK4 are 3.4, 4.4 and 4.8 kb, respectively.

7. Example: Genomic Sequence Of The PAK5 Gene

Oligonucleotides 5'-GAGTGACTCCATCCTGC-3' (SEQ ID NO: 18) and 5'-GTAGGGGGTTCCCACCA-3' (SEQ ID NO: 19) were used to identify a genomic clone from a commercially available P1 human library (Genome Systems, Inc., St. Louis, MO) that contained the PAK5 gene. The P1 genomic clone was partially sequenced, and additional coding sequence deduced. The polynucleotide sequence, with deduced exons indicated, is presented as SEQ ID NO:7. SEQ ID NO:8 presents the deduced amino acid sequence from

the partial genomic sequence. A partial schematic structure of the PAK5 gene is depicted in Figure 1. A PLC-2 gene was found to be linked to the PAK5 gene in the P1 clone. The PLC-2 gene has been mapped to chromosome 15; thus, the PAK5 gene also must reside on chromosome 15.

5 The deduced amino acid sequence of the PAK5 protein (SEQ ID NO:8) is very similar to that of PAK4 (SEQ ID NO:4), especially in the kinase domain (amino acid residues 93 to 311 in SEQ ID NO:8). The kinase domains of any of the JNKKKs of the present invention have utility as enzymatically active domains to phosphorylate substrates. The sequence of the PAK5 kinase domain contains a conserved lysine (K) residue that is essential for ATP
10 binding (amino acid residue 120 in SEQ ID NO:8). By analogy with PAK4, mutations that change this lysine residue in PAK5 to alanine or methionine residues will abolish PAK5 enzymatic activity, while mutations that change the lysine residue to a glutamine will make a full length PAK5 protein constitutively active. Less homology between PAK4 and PAK5 is observed outside of the kinase domain. The 21 residue carboxy terminal extension of PAK5
15 is 4 amino acids longer than that of PAK4. Additionally, the available amino terminal sequences of the PAK5 protein bear no similarity to any known protein other than PAK4. Thus, both the carboxy terminal and the amino terminal regions of the PAK5 protein will be particularly useful in generating antibodies that immunospecifically recognize PAK5.

 The ORF of the complete human cDNA sequence of PAK5 is presented in SEQ ID
20 NO:9 from nt 199-2244. The complete DNA sequence for the human PAK5 gene is presented in SEQ ID NO:10, with the ORF from nt 6125-17433.

8. Example: Ultraviolet Radiation-Induced Expression Of YSK2 And PAK5 mRNA

 In this example, the effect of various wavelengths of ultraviolet radiation on the expression of the novel JNKKKs was investigated. The effects of both UV-C light (short
25 wavelength ultraviolet radiation of 220 to 290 nm) and UV-A light (long wavelength ultraviolet radiation of 320 to 400 nm) were separately analyzed.

 Keratinocytes were grown as described in Section 6.1, above. The cells were expanded through two 1:4 passages before illumination with 3-10 mJ/cm² of UV-C light or 1-5 J/cm² of UV-A light. Cells were harvested 6 or 24 hours after exposure. PolyA mRNA was
30 purified from the cells using kits from Qiagen.

 Figure 3A shows that the YSK2 gene is induced by UV-C light. Keratinocytes were exposed to 10 mJ/cm² of UV-C light. Messenger RNAs from control and UV-C light- treated cells were separated by electrophoresis and transferred to a membrane by Northern blotting. The membrane was then hybridized using the 190 bp YSK2 RT-PCR product labeled with
35 ³²P-dNTPs as the probe. As Figure 3A shows, the expression of the YSK2 gene in keratinocytes was greatly enhanced by UV-C light exposure.

 Figure 3B shows that the PAK5 gene is induced by UV-A light treatment. Human

keratinocytes were exposed to UV-A light (5 mJ/cm²), harvested, and mRNA prepared from the cells. The levels of PAK4 and PAK5 mRNA in treated and untreated cells were compared using differential display. Liang and Pardee, 1992, Science 257:967-71. Amplification was performed using primer SEQ ID NOS:14 and 15, or SEQ ID NO:16 and 17, above. The resulting amplified DNA was then digested with restriction enzyme TaqI to reveal specifically the PAK4 and the PAK5 DNAs. The results demonstrate that PAK5 is induced by ultraviolet radiation.

Differential display experiments (Figures 3A and 3B) show that expression of both YSK2 and PAK5 genes are induced by ultraviolet radiation. However, induction of the two genes is dependent upon the wavelength of the ultraviolet radiation. YSK2 gene expression is induced by UV-C, which is the short wavelength ultraviolet radiation (220 to 290 nm). In contrast, the PAK5 gene expression is induced by UV-A, which is the long wavelength ultraviolet radiation (320 to 400 nm). The induction of YSK2 and PAK5 gene expression by ultraviolet radiation suggests that the products of the two genes are involved in the signal transduction cascade that transduces extracellular ultraviolet radiation (or other stress signals). Although MLK4 and PAK4 mRNA gene expression were not induced by ultraviolet radiation in these experiments, this fact cannot rule out a role in the keratinocyte response to light or other stresses. These gene products can be involved in the early cellular events in response to stress prior to any changes in gene expression.

The foregoing written specification is sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the above-described means for carrying out the invention which are obvious to those skilled in the field of molecular biology, medicine or related fields are intended to be within the scope of the following claims.

All references referred to herein above are incorporated herein by reference in their entirety.

CLAIMS

What is claimed is:

1. An isolated polynucleotide molecule comprising a nucleotide sequence encoding an MLK4 gene product from a human, wherein the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2.
5
2. The isolated polynucleotide sequence of claim 1 comprising the nucleotide sequence of SEQ ID NO:1.
3. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:1.
- 10 4. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding an MLK4 gene product from a human, wherein the MLK4 gene product comprises the amino acid sequence of SEQ ID NO:2.
- 15 5. The isolated polynucleotide molecule of claim 4, wherein the nucleotide sequence encoding the MLK4 gene product comprises the nucleotide sequence of SEQ ID NO:1.
6. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK4 gene product from a human, wherein the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4.
- 20 7. The isolated polynucleotide sequence of claim 6 comprising the nucleotide sequence of SEQ ID NO:3.
8. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:3.
- 25 9. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding a PAK4 gene product from a human, wherein the PAK4 gene product comprises the amino acid sequence of SEQ ID NO:4.
10. The isolated polynucleotide molecule of claim 9, wherein the nucleotide sequence encoding the PAK4 gene product comprises the nucleotide sequence of SEQ ID NO:3.
- 30 11. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a PAK5 gene product from a human, wherein the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10
- 35 12. The isolated polynucleotide sequence of claim 11, comprising the nucleotide sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 from nt 199 to nt 2244, or SEQ ID NO:11 from nt 6125 to nt 17433.
13. An isolated polynucleotide molecule comprising the nucleotide sequence of

an exon of SEQ ID NO:7.

14. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 from nt 199 to nt 2244, or SEQ ID NO:11 from nt 6125 to nt 17433.

5 15. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding a PAK5 gene product from a human, wherein the PAK5 gene product comprises the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10.

10 16. The isolated polynucleotide molecule of claim 15, wherein the nucleotide sequence encoding the PAK5 gene product comprises the nucleotide sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 from nt 199 to nt 2244, or SEQ ID NO:11 from nt 6125 to nt 17433.

15 17. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a YSK2 gene product from a human, wherein the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13.

18. The isolated polynucleotide sequence of claim 17, comprising the nucleotide sequence of SEQ ID NO:12.

19. An isolated polynucleotide molecule that is homologous to a polynucleotide molecule comprising the nucleotide sequence of SEQ ID NO:12.

20 20. An isolated polynucleotide molecule consisting of a nucleotide sequence that is a substantial portion of a polynucleotide molecule comprising a nucleotide sequence encoding a YSK2 gene product from a human, wherein the YSK2 gene product comprises the amino acid sequence of SEQ ID NO:13.

25 21. The isolated polynucleotide molecule of claim 20, wherein the nucleotide sequence encoding the YSK2 gene product comprises the nucleotide sequence of SEQ ID NO:12.

22. A recombinant vector comprising any of the polynucleotide molecules of claims 1, 6, 11 or 17.

23. A transformed host cell comprising the recombinant vector of claim 22.

30 24. A substantially purified or isolated polypeptide comprising a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:13.

35 25. A method of preparing a substantially purified or isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:13, comprising culturing host cells of claim 23 under conditions conducive to the expression of the polypeptide or peptide fragment, and recovering in substantially purified or isolated form the

polypeptide or peptide fragment from the cell culture.

26. An isolated antibody specific for a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:13.

5 27. The isolated antibody of claim 26 which is specific for amino acid residues 1-10 of SEQ ID NO:13.

28. A method of screening for compounds that affect the cellular levels of a JNKKK gene product, comprising:

- 10 a) applying a test compound to a cellular test sample;
- b) determining the cellular level of at least one JNKKK gene product in the test sample wherein the gene product is a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:13 or an mRNA encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10 and SEQ ID NO:13; and
- 15 c) comparing the levels of the gene product in the test sample with that in a reference sample;

20 wherein a specific change in the cellular levels of the gene product in the test sample as compared to the reference sample indicates that the compound affects the cellular levels of gene product from a JNKKK gene.

29. The method of claim 28, wherein the gene product is an mRNA.

30. The method of claim 28 further comprising the step of applying a stress event to the test sample, and determining the effect of the test compound on the response of the test sample to the stress event.

31. The method of claim 28, wherein the stress event is exposure to ultraviolet radiation.

32. The method of claim 29, wherein the stress event is exposure to an inflammatory cytokine.

33. The method of claim 28, wherein the test and reference samples are cultured cells.

34. The method of claim 28, wherein the test and reference samples are cultured skin tissues.

35 35. The method of claim 28, wherein the test and reference samples are animals.

36. A method of screening for compounds that affect the activity of a JNKKK, the method comprising:

- 5
- a) applying a test compound to a test sample;
 - b) determining the activity of a JNKKK in the test sample and a reference sample, wherein the JNKKK comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:13;

10 wherein a test compound that alters the JNKKK activity in the test sample as compared to the reference sample is identified as a compound that affects the activity of the JNKKK.

37. The method of claim 36, wherein the step of determining the activity of the JNKKK comprises determining kinase activity of the JNKKK.

15 38. The method of claim 36, further comprising the step of applying a stress event to the test sample and determining the effect of the test compound on the response of the test sample to the stress event.

39. The method of claim 38, wherein the stress event is ultra-violet radiation.

40. The method of claim 38, wherein the stress event is an inflammatory cytokine.

20 41. The method of claim 36, wherein the test and reference samples are cultured cells.

42. The method of claim 36 wherein the test and reference samples are cultured skin tissues.

25 43. A method for identifying a compound that binds to a PAK5 polypeptide comprising the amino acid sequence of SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:10, or that binds to a YSK2 polypeptide comprising the amino acid sequence of SEQ ID NO:13, comprising:

- a) contacting a test compound with the polypeptide for a time sufficient to form polypeptide/compound complex; and
 - b) detecting the complex;
- 30 so that if a polypeptide/test compound complex is detected, a compound that binds to the PAK5 polypeptide or YSK2 polypeptide is identified.

44. A method of screening for compounds that affect the expression of a gene that encodes a JNKKK gene product, comprising:

- 35
- (a) applying a test compound to a test sample;
 - (b) determining the expression level of at least one gene in cells of the test sample, wherein the gene encodes a JNKKK gene product comprising an amino acid sequence selected from the group

consisting of SEQ ID NOS:2, 4, 6, 8, 10 and 13; and

- (c) comparing the expression level of the gene in the test sample with that in a reference sample;

wherein a specific change in the expression of the gene in the test sample as compared to the reference sample indicates that the test compound affects the expression of the gene.

45. The method of claim 44, further comprising the step of applying a stress event to the test sample and determining the effect of the test compound on the gene expression response of the test sample to the stress event.

46. A method of detecting an MLK4-, PAK4-, PAK5- or YSK2-related polynucleotide in a sample, comprising contacting the sample with a compound that binds to and forms a complex with the particular polynucleotide for a period of time sufficient to form the complex, and detecting the complex, so that if a complex is detected, the MLK4, PAK4, PAK5 or YSK2-related polynucleotide, respectively, is detected.

47. The method of claim 46, wherein the method comprises contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the particular polynucleotide under such hybridization conditions, and amplifying the annealed polynucleotides, so that if a particular polynucleotide is amplified, the MLK4-, PAK4-, PAK5- or YSK2-related polynucleotide, respectively, is detected.

Genes And Polypeptides Associated With Ultraviolet Radiation-Mediated Skin Damage And Uses Thereof

Abstract

5 The invention relates to novel polynucleotides and their encoded gene products that are expressed in skin cells, particularly keratinocytes, and methods of using the same. Specifically, the present invention provides polynucleotides encoding several novel protein kinases that are c-Jun N-terminal kinase kinase kinases, i.e., MLK4, PAK4, PAK5 and YSK2. In addition, the invention provides methods of using the disclosed polynucleotides and their
10 gene products in drug discovery, particularly in screening for drugs that can reduce ultraviolet light-induced damage of the skin, inflammation and psoriasis, and drugs that can enhance wound healing.




FIG. 1





FIG. 2

Northern blot

Control UVC



10 mJ/cm²
1 hr post
illumination

FIG. 3A




FIG. 3B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: :

BLUMENBERG and GAZEL

SERIAL NO.: To be assigned :

FILED: Concurrently herewith : Examiner: To be assigned

FOR: GENES AND POLYNUCLEOTIDES : Art Unit: To be assigned
ASSOCIATED WITH ULTRAVIOLET
RADIATION-MEDIATED SKIN
DAMAGE AND USES THEREOF

STATEMENT REGARDING SEQUENCE LISTING

BOX PATENT APPLICATION


Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The above-identified application, filed concurrently herewith, contains a Sequence Listing in both paper copy and on computer diskette. Attorney for Applicant has compared the contents of the paper copy of the Sequence Listing with the contents of the diskette, and states that they are identical to each other.

Respectfully submitted,

Date: September 11, 2000


Alan L. Koller
Reg. No. 37,371
Attorney for Applicants

BY HAND

SEQUENCE LISTING

<110> Blumenberg, Miroslav
Gazel, Alix M

<120> GENES AND POLYNUCLEOTIDES ASSOCIATED WITH ULTRAVIOLET
RADIATION-MEDIATED SKIN DAMAGE AND USES THEREOF

<130> PC10489A

<140>

<141>

<150> 60/155,029

<151> 1999-09-20

<160> 19

<170> PatentIn Ver. 2.1

<210> 1

<211> 164

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (2)..(163)

<400> 1

g cac cgg gac atc aag gca gga aat att ttg cta ctt gag aag ata gaa 49
His Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Leu Glu Lys Ile Glu
1 5 10 15

cat gat gac atc tgc aat aaa act ttg aag att aca gat ttt ggg ttg 97
His Asp Asp Ile Cys Asn Lys Thr Leu Lys Ile Thr Asp Phe Gly Leu
20 25 30

gcg agg gaa tgg cac agg acc acc aaa atg agc aca gca ggc acc tat 145
Ala Arg Glu Trp His Arg Thr Thr Lys Met Ser Thr Ala Gly Thr Tyr
35 40 45

gcc tgg atg gcc cca gaa g 164
Ala Trp Met Ala Pro Glu
50

<210> 2

<211> 54
<212> PRT
<213> Homo sapiens

<400> 2
His Arg Asp Ile Lys Ala Gly Asn Ile Leu Leu Leu Glu Lys Ile Glu
1 5 10 15
His Asp Asp Ile Cys Asn Lys Thr Leu Lys Ile Thr Asp Phe Gly Leu
20 25 30
Ala Arg Glu Trp His Arg Thr Thr Lys Met Ser Thr Ala Gly Thr Tyr
35 40 45
Ala Trp Met Ala Pro Glu
50

<210> 3
<211> 145
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (2)..(145)

<400> 3
a cat cgg gac atc aag agc gac tcg atc ctg ctg acc cat gat ggc agg 49
His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr His Asp Gly Arg
1 5 10 15
gtg aag ctg tca gac ttt ggg ttc tgc gcc cag gtg agc aag gaa gtg 97
Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Val Ser Lys Glu Val
20 25 30
ccc cga agg aag tcg ctg gtc ggc acg ccc tac tgg atg gcc cca gag 145
Pro Arg Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu
35 40 45

<210> 4
<211> 48
<212> PRT
<213> Homo sapiens

<400> 4

His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr His Asp Gly Arg
 1 5 10 15

Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Val Ser Lys Glu Val
 20 25 30

Pro Arg Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu
 35 40 45

<210> 5
 <211> 146
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (2)..(145)

<400> 5
 t cac agg gac atc aag agt gac tcc atc ctg ctg acc ctc gat ggc agg 49
 His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg
 1 5 10 15

gtg aag ctc tcg gac ttc gga ttc tgt gct cag atc agc aaa gac gtc 97
 Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val
 20 25 30

cct aag agg aag tcc ctg gtg gga acc ccc tac tgg atg gcg ccc gag g 146
 Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu
 35 40 45

<210> 6
 <211> 48
 <212> PRT
 <213> Homo sapiens

<400> 6
 His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg
 1 5 10 15

Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val
 20 25 30

Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu
 35 40 45

<210> 7
<211> 3627
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (868)..(1275)

<220>
<221> CDS
<222> (1420)..(1553)

<220>
<221> CDS
<222> (1900)..(2026)

<220>
<221> CDS
<222> (2105)..(2230)

<220>
<221> CDS
<222> (2696)..(2833)

<400> 7
gatctgcgac ctccttcaga acctgccaaa atgactagga aaaatgctgt ttccatagca 60
agagccaaaa gagaacatga cggccctgca ctccgggata tctctggcac cagattccca 120
gcccagggga gacacctgaa ccccccagat ggtgacacac ctctgtggtc ctctgtcagg 180
gacataacct ccagcacag atttgcaaac tccctgctgc aggcacaagc agggctatcg 240
ggccccaggt gtggctcccc tgccttggtt caggagtggt agacacagtt gccactgct 300
ccccaccca ctgccaggcc tcttctgccc ccatgggtcc tgggggtgggg gagccttggg 360
agttgaagaa tgcctctgac ccagattott caagcagcct ctgagctcag aggaagagtc 420
tgcctcacgg cagcctccct ggggtotagc tgtcaatgc ccaggaagaa ataccagcg 480
cgggacccgg cggggaagct ggccttotct gtottoccag gtgcagcaca gcgagtgtaa 540
ggagctgtct tgggcctgcc cagcctgggt ccttgcgggg gactgctggc acaggactgt 600

gactgggctt cagctctgtc tgaaaatctt tgcttcagag cacctcccta gtttgatctg 660
 ataccccgcc tgaccctgcc agagtccaga ggtcacggcg gccagcccct gcctccggga 720
 aggttatctc aaatgctccc acagccctga cccttctgt tgctttgtcc cttgcagccc 780
 aactcctctt tccgaccgcc gcagaaagac aaccccccaa gcctggtggc caaggcccag 840
 tccttgccct cggaccagcc ggtgggg acc ttc agc cct ctg acc act tcg gat 894
 Thr Phe Ser Pro Leu Thr Thr Ser Asp
 1 5

acc agc agc ccc cag aag tcc ctc cgc aca gcc ccg gcc aca ggc cag 942
 Thr Ser Ser Pro Gln Lys Ser Leu Arg Thr Ala Pro Ala Thr Gly Gln
 10 15 20 25

ctt cca ggc cgg tct tcc cca gcg gga tcc ccc cgc acc tgg cac gcc 990
 Leu Pro Gly Arg Ser Ser Pro Ala Gly Ser Pro Arg Thr Trp His Ala
 30 35 40

cag atc agc acc agc aac ctg tac ctg ccc cag gac ccc acg gtt gcc 1038
 Gln Ile Ser Thr Ser Asn Leu Tyr Leu Pro Gln Asp Pro Thr Val Ala
 45 50 55

aag ggt gcc ctg gct ggt gag gac aca ggt gtt gtg aca cat gag cag 1086
 Lys Gly Ala Leu Ala Gly Glu Asp Thr Gly Val Val Thr His Glu Gln
 60 65 70

ttc aag gct gcg ctc agg atg gtg gtg gac cag ggt gac ccc cgg ctg 1134
 Phe Lys Ala Ala Leu Arg Met Val Val Asp Gln Gly Asp Pro Arg Leu
 75 80 85

ctg ctg gac agc tac gtg aag att ggc gag ggc tcc acc ggc atc gtc 1182
 Leu Leu Asp Ser Tyr Val Lys Ile Gly Glu Gly Ser Thr Gly Ile Val
 90 95 100 105

tgc ttg gcc cgg gaa gaa cac tcg ggc cgc cag gtg gcc gtc aag atg 1230
 Cys Leu Ala Arg Glu Glu His Ser Gly Arg Gln Val Ala Val Lys Met
 110 115 120

atg gac ctc aga aag cag cag cgc agg gag ctg ctc ttc aac gag 1275
 Met Asp Leu Arg Lys Gln Gln Arg Arg Glu Leu Leu Phe Asn Glu
 125 130 135

gtgggaggac aggggtgggac acacacgggg gcgttgggga tgggcagtga gcagccagcc 1335

aggctggaca tctgtgagca ggggcagtgg gtggccatgc gtctgggcac tgtgcctggc 1395

actcaggccc ccacctgccc ccag gtg gtg atc atg cgg gac tac cag cac 1446
Val Val Ile Met Arg Asp Tyr Gln His
140 145

ttc aac gtg gtg gag atg tac aag agc tac ctg gtg ggc gag gag ctg 1494
Phe Asn Val Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu Glu Leu
150 155 160

tgg gtg ctc atg gag ttc ctg cag gga gga gcc ctc aca gac atc gtc 1542
Trp Val Leu Met Glu Phe Leu Gln Gly Gly Ala Leu Thr Asp Ile Val
165 170 175

tcc caa gtc ag gtgggcagct gggagggctg gaccctgagt gcaggctgcc 1593
Ser Gln Val Arg
180

ctcaccatgg ccttgccagg gcaatgtggt cttctgcctg tggcccagaa gacttgggat 1653

gcctgggctc ccttgctgc tggggtaact gagaccagc ggtcttgga gtggagaaga 1713

gaaggatagc ttctagccaa agctcaggcc ccagttttca ccagggctat ggctgactg 1773

tgctgcaaaa cagattgcct gggagctgtg gggcctagca ccagggactc ctactotgct 1833

cagccacccc acgacctgcc agagctaacg ttctctttca tcgggtggcc ccaccttcct 1893

gtccag g ctg aat gag gag cag att gcc act gtg tgt gag gct gtg ctg 1942
Leu Asn Glu Glu Gln Ile Ala Thr Val Cys Glu Ala Val Leu
185 190 195

cag gcc ctg gcc tac ctg cat gct cag ggt gtc atc cac cgg gac atc 1990
Gln Ala Leu Ala Tyr Leu His Ala Gln Gly Val Ile His Arg Asp Ile
200 205 210

aag agt gac tcc atc ctg ctg acc ctc gat ggc agg gtaggtccca 2036
Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg
215 220

tcctgtccct ggcacagcca cgctcccact tcctcctgat ccaccactca ctcccttttc 2096

aaccgcag gtg aag ctc tcg gac ttc gga ttc tgt gct cag atc agc aaa 2146
Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys
225 230 235

gac gtc cct aag agg aag tcc ctg gtg gga acc ccc tac tgg atg gct 2194
Asp Val Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala
240 245 250

cct gaa gtg atc tcc agg tct ttg tat gcc act gag gtaaccgttc 2240
Pro Glu Val Ile Ser Arg Ser Leu Tyr Ala Thr Glu
255 260 265

cctccacccc ccagacctcc caaaagcaac ttggcaactg gcagctcttc tgctgtggcc 2300
cctccagtga gctcaccaaa agcagccctg gttttcagag tcccacctag tcaacaccct 2360
tccccctttc gatggggctg ctcttacctg gtgactttgc tgccaggaac gagtcctgca 2420
agtgttttcc tcagctcaag ggcagaatgg ggtatggccg ggctctctat gtatgatggc 2480
ctttctctga gtgactgaca gctgtgtccc tataggcagt ggtcactcat gcaggcagta 2540
actggccaca gggcaggtga ccaggggagg aaggagacag accaccaag gagagctggg 2600
gccagctgtc cccctccac cactgctgcc accagaacgc agctaccaat gggccagggt 2660
ctggccatgg ggtcaggagc attttcctcc tgcag gtg gat atc tgg tct ctg 2713
Val Asp Ile Trp Ser Leu
270

ggg atc atg gtg att gag atg gta gat ggg gag cca ccg tac ttc agt 2761
Gly Ile Met Val Ile Glu Met Val Asp Gly Glu Pro Pro Tyr Phe Ser
275 280 285

gac tcc cca gtg caa gcc atg aag agg ctc cgg gac agc ccc cca ccc 2809
Asp Ser Pro Val Gln Ala Met Lys Arg Leu Arg Asp Ser Pro Pro Pro
290 295 300

aag ctg aaa aac tct cac aag gtc agttggcaca caagggtgcg acctcgaga 2863
Lys Leu Lys Asn Ser His Lys Val
305 310

ccccattcct cctgaggcaa ggggaccaga acctgggctc ccagcatctc ccttccactg 2923
aagccacagg gtctgggctc ctggaaaagg ctctctttc cccacacaaa acccgcacct 2983
gggtgtggag ccgcatctac gcacaagttc gcatgtgcgc tccgacaagt cgcctccac 3043
ggctgtggca ggagagttgc tgcttggcag aagggttgct gcttggcagg cactggtcgg 3103
aagcccagtg gggcccatga gcagggaaag ccaggacacc agcaactccc tgctgtccag 3163
ggagggatcc ggagaagctt cactgagcac aaacccttca acccgtgtcg ggagatccat 3223
accatgattc gatgtccctg tccatcacgg cgagtcggct catgctccat tcgttgaca 3283

ccccgacaca gctaagccac agcgttcccc ttaaagccag tataagtgca tggaagtgg 3343
 atacatgtaa ccctttttgc caaatcggcc ccaaccccgcc aggccttact gtggacgccc 3403
 cctgctggca ggtcagcacg gggctgataa gtggcaccgc catctggtgg ccaaaacaag 3463
 aaatgtctca gagggctgaa gcctctcctc taaaatagca aaaaaacaag agttctgtgg 3523
 ccccaacaca aagctggatg ggaggaccaa caggaaacat cttccaagac aactggctct 3583
 tggagcccgcc accgctaacc ccaaaattag catataaagc atgc 3627

<210> 8

<211> 311

<212> PRT

<213> Homo sapiens

<400> 8

Thr Phe Ser Pro Leu Thr Thr Ser Asp Thr Ser Ser Pro Gln Lys Ser
 1 5 10 15

Leu Arg Thr Ala Pro Ala Thr Gly Gln Leu Pro Gly Arg Ser Ser Pro
 20 25 30

Ala Gly Ser Pro Arg Thr Trp His Ala Gln Ile Ser Thr Ser Asn Leu
 35 40 45

Tyr Leu Pro Gln Asp Pro Thr Val Ala Lys Gly Ala Leu Ala Gly Glu
 50 55 60

Asp Thr Gly Val Val Thr His Glu Gln Phe Lys Ala Ala Leu Arg Met
 65 70 75 80

Val Val Asp Gln Gly Asp Pro Arg Leu Leu Leu Asp Ser Tyr Val Lys
 85 90 95

Ile Gly Glu Gly Ser Thr Gly Ile Val Cys Leu Ala Arg Glu Glu His
 100 105 110

Ser Gly Arg Gln Val Ala Val Lys Met Met Asp Leu Arg Lys Gln Gln
 115 120 125

Arg Arg Glu Leu Leu Phe Asn Glu Val Val Ile Met Arg Asp Tyr Gln
 130 135 140

His Phe Asn Val Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu Glu

145		150		155		160
Leu Trp Val	Leu Met Glu Phe	Leu Gln Gly Gly	Ala Leu Thr	Asp Ile		
	165	170		175		
Val Ser Gln	Val Arg Leu Asn	Glu Glu Gln Ile	Ala Thr Val	Cys Glu		
	180	185		190		
Ala Val Leu	Gln Ala Leu Ala	Tyr Leu His	Ala Gln Gly	Val Ile His		
	195	200		205		
Arg Asp Ile	Lys Ser Asp Ser	Ile Leu Leu Thr	Leu Asp Gly	Arg Val		
	210	215		220		
Lys Leu Ser	Asp Phe Gly Phe	Cys Ala Gln Ile	Ser Lys Asp	Val Pro		
	225	230		235		240
Lys Arg Lys	Ser Leu Val Gly	Thr Pro Tyr Trp	Met Ala Pro	Glu Val		
	245	250		255		
Ile Ser Arg	Ser Leu Tyr Ala	Thr Glu Val Asp	Ile Trp Ser	Leu Gly		
	260	265		270		
Ile Met Val	Ile Glu Met Val	Asp Gly Glu Pro	Pro Tyr Phe	Ser Asp		
	275	280		285		
Ser Pro Val	Gln Ala Met Lys	Arg Leu Arg Asp	Ser Pro Pro	Pro Lys		
	290	295		300		
Leu Lys Asn	Ser His Lys Val					
305	310					

<210> 9

<211> 2669

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (199)..(2244)

<400> 9

gagtgcgcgt tcctgggcta gagacaagca ccagcctgca gtggagaacg caggaccccg 60

ctgcccagaa ggagcagcca cggcctgcgg aggactggcc cagcaaggtc ccaggtcttc 120

cctctcctca gcgcctaaga gagaggccca gtgcgggtga ggagtcgcga ggaagaggcg 180

gaaggcgccg gaaggacc atg ttc cgc aag aaa aag aag aaa cgc cct gag 231
Met Phe Arg Lys Lys Lys Lys Lys Arg Pro Glu
1 5 10

atc tca gcg cca cag aac ttc cag cac cgt gtc cac acc tcc ttc gac 279
Ile Ser Ala Pro Gln Asn Phe Gln His Arg Val His Thr Ser Phe Asp
15 20 25

ccc aaa gaa ggc aag ttt gtg ggc ctc ccc cca caa tgg cag aac atc 327
Pro Lys Glu Gly Lys Phe Val Gly Leu Pro Pro Gln Trp Gln Asn Ile
30 35 40

ctg gac aca ctg cgg cgc ccc aag ccc gtg gtg gac cct tcg cga atc 375
Leu Asp Thr Leu Arg Arg Pro Lys Pro Val Val Asp Pro Ser Arg Ile
45 50 55

aca cgg gtg cag ctc cag ccc atg aag aca gtg gtg cgg ggc agc gcg 423
Thr Arg Val Gln Leu Gln Pro Met Lys Thr Val Val Arg Gly Ser Ala
60 65 70 75

atg cct gtg gat ggc tac atc tcg ggg ctg ctc aac gac atc cag aag 471
Met Pro Val Asp Gly Tyr Ile Ser Gly Leu Leu Asn Asp Ile Gln Lys
80 85 90

ttg tca gtc atc agc tcc aac acc ctg cgt ggt cgc agc ccc acc agc 519
Leu Ser Val Ile Ser Ser Asn Thr Leu Arg Gly Arg Ser Pro Thr Ser
95 100 105

cgg cgg cgg gca cag tcc ctg ggg ctg ctg ggg gat gag cac tgg gcc 567
Arg Arg Arg Ala Gln Ser Leu Gly Leu Leu Gly Asp Glu His Trp Ala
110 115 120

acc gac cca gac atg tac ctc cag agc ccc cag tct gag cgc act gac 615
Thr Asp Pro Asp Met Tyr Leu Gln Ser Pro Gln Ser Glu Arg Thr Asp
125 130 135

ccc cac ggc ctc tac ctc agc tgc aac ggg ggc aca cca gca ggc cac 663
Pro His Gly Leu Tyr Leu Ser Cys Asn Gly Gly Thr Pro Ala Gly His
140 145 150 155

aag cag atg cgg tgg ccc gag cca cag agc cca cgg gtc ctg ccc aat 711
Lys Gln Met Pro Trp Pro Glu Pro Gln Ser Pro Arg Val Leu Pro Asn
160 165 170

ggg ctg gct gca aag gca cag tcc ctg ggc ccc gcc gag ttt cag ggt 759
Gly Leu Ala Ala Lys Ala Gln Ser Leu Gly Pro Ala Glu Phe Gln Gly

175	180	185	
gcc tcg cag cgc tgt ctg cag ctg ggt gcc tgc ctg cag agc tcc cca			807
Ala Ser Gln Arg Cys Leu Gln Leu Gly Ala Cys Leu Gln Ser Ser Pro			
190	195	200	
cca gga gcc tcg ccc ccc acg ggc acc aat agg cat gga atg aag gct			855
Pro Gly Ala Ser Pro Pro Thr Gly Thr Asn Arg His Gly Met Lys Ala			
205	210	215	
gcc aag cat ggc tct gag gag gcc cgg cca cag tcc tgc ctg gtg ggc			903
Ala Lys His Gly Ser Glu Glu Ala Arg Pro Gln Ser Cys Leu Val Gly			
220	225	230	235
tca gcc aca ggc agg cca ggt ggg gaa ggc agc cct agc cct aag acc			951
Ser Ala Thr Gly Arg Pro Gly Gly Glu Gly Ser Pro Ser Pro Lys Thr			
240	245	250	
cgg gag agc agc ctg aag cgc agg cta ttc cga agc atg ttc ctg tcc			999
Arg Glu Ser Ser Leu Lys Arg Arg Leu Phe Arg Ser Met Phe Leu Ser			
255	260	265	
act gct gcc aca gcc cct cca agc agc agc aag cca ggc cct cca cca			1047
Thr Ala Ala Thr Ala Pro Pro Ser Ser Ser Lys Pro Gly Pro Pro Pro			
270	275	280	
cag agc aag ccc aac tcc tct ttc cga ccg ccg cag aaa gac aac ccc			1095
Gln Ser Lys Pro Asn Ser Ser Phe Arg Pro Pro Gln Lys Asp Asn Pro			
285	290	295	
cca agc ctg gtg gcc aag gcc cag tcc ttg ccc tcg gac cag ccg gtg			1143
Pro Ser Leu Val Ala Lys Ala Gln Ser Leu Pro Ser Asp Gln Pro Val			
300	305	310	315
ggg acc ttc agc cct ctg acc act tcg gat acc agc agc ccc cag aag			1191
Gly Thr Phe Ser Pro Leu Thr Thr Ser Asp Thr Ser Ser Pro Gln Lys			
320	325	330	
tcc ctc cgc aca gcc ccg gcc aca ggc cag ctt cca ggc cgg tct tcc			1239
Ser Leu Arg Thr Ala Pro Ala Thr Gly Gln Leu Pro Gly Arg Ser Ser			
335	340	345	
cca gcg gga tcc ccc cgc acc tgg cac gcc cag atc agc acc agc aac			1287
Pro Ala Gly Ser Pro Arg Thr Trp His Ala Gln Ile Ser Thr Ser Asn			
350	355	360	
ctg tac ctg ccc cag gac ccc acg gtt gcc aag ggt gcc ctg gct ggt			1335
Leu Tyr Leu Pro Gln Asp Pro Thr Val Ala Lys Gly Ala Leu Ala Gly			

365	370	375	
gag gac aca ggt gtt gtg aca cat gag cag ttc aag gct gcg ctc agg			1383
Glu Asp Thr Gly Val Val Thr His Glu Gln Phe Lys Ala Ala Leu Arg			
380	385	390	395
atg gtg gtg gac cag ggt gac ccc cgg ctg ctg ctg gac agc tac gtg			1431
Met Val Val Asp Gln Gly Asp Pro Arg Leu Leu Leu Asp Ser Tyr Val			
	400	405	410
aag att ggc gag ggc tcc acc ggc atc gtc tgc ttg gcc cgg gag aag			1479
Lys Ile Gly Glu Gly Ser Thr Gly Ile Val Cys Leu Ala Arg Glu Lys			
	415	420	425
cac tcg ggc cgc cag gtg gcc gtc aag atg atg gac ctc agg aag cag			1527
His Ser Gly Arg Gln Val Ala Val Lys Met Met Asp Leu Arg Lys Gln			
	430	435	440
cag cgc agg gag ctg ctc ttc aac gag gtg gtg atc atg cgg gac tac			1575
Gln Arg Arg Glu Leu Leu Phe Asn Glu Val Val Ile Met Arg Asp Tyr			
	445	450	455
cag cac ttc aac gtg gtg gag atg tac aag agc tac ctg gtg gga gag			1623
Gln His Phe Asn Val Val Glu Met Tyr Lys Ser Tyr Leu Val Gly Glu			
460	465	470	475
gag ctg tgg gtg ctc atg gag ttc ctg cag gga gga gcc ctc aca gac			1671
Glu Leu Trp Val Leu Met Glu Phe Leu Gln Gly Gly Ala Leu Thr Asp			
	480	485	490
atc gtc tcc caa gtc agg ctg aat gag gag cag att gcc act gtg tgt			1719
Ile Val Ser Gln Val Arg Leu Asn Glu Glu Gln Ile Ala Thr Val Cys			
	495	500	505
gag gct gtg ctg cag gcc ctg gcc tac ctg cat gct cag ggt gtc atc			1767
Glu Ala Val Leu Gln Ala Leu Ala Tyr Leu His Ala Gln Gly Val Ile			
	510	515	520
cac cgg gac atc aag agt gac tcc atc ctg ctg acc ctc gat ggc agg			1815
His Arg Asp Ile Lys Ser Asp Ser Ile Leu Leu Thr Leu Asp Gly Arg			
	525	530	535
gtg aag ctc tcg gac ttc gga ttc tgt gct cag atc agc aaa gac gtc			1863
Val Lys Leu Ser Asp Phe Gly Phe Cys Ala Gln Ile Ser Lys Asp Val			
540	545	550	555
cct aag agg aag tcc ctg gtg gga acc ccc tac tgg atg gct cct gaa			1911
Pro Lys Arg Lys Ser Leu Val Gly Thr Pro Tyr Trp Met Ala Pro Glu			

560	565	570	
gtg atc tcc agg tct ttg tat gcc act gag gtg gat atc tgg tct ctg			1959
Val Ile Ser Arg Ser Leu Tyr Ala Thr Glu Val Asp Ile Trp Ser Leu			
575	580	585	
ggc atc atg gtg att gag atg gta gat ggg gag cca ccg tac ttc agt			2007
Gly Ile Met Val Ile Glu Met Val Asp Gly Glu Pro Pro Tyr Phe Ser			
590	595	600	
gac tcc cca gtg caa gcc atg aag agg ctc cgg gac agc ccc cca ccc			2055
Asp Ser Pro Val Gln Ala Met Lys Arg Leu Arg Asp Ser Pro Pro Pro			
605	610	615	
aag ctg aaa aac tct cac aag gtc tcc cca gtg ctg cga gac ttc ctg			2103
Lys Leu Lys Asn Ser His Lys Val Ser Pro Val Leu Arg Asp Phe Leu			
620	625	630	635
gag cgg atg ctg gtg cgg gac ccc caa gag aga gcc aca gcc cag gag			2151
Glu Arg Met Leu Val Arg Asp Pro Gln Glu Arg Ala Thr Ala Gln Glu			
640	645	650	
ctc cta gac cac ccc ttc ctg ctg cag aca ggg cta cct gag tgc ctg			2199
Leu Leu Asp His Pro Phe Leu Leu Thr Gly Leu Pro Glu Cys Leu			
655	660	665	
gtg ccc ctg atc cag ctc tac cga aag cag acc tcc acc tgc tga			2244
Val Pro Leu Ile Gln Leu Tyr Arg Lys Gln Thr Ser Thr Cys			
670	675	680	
gcccaccca agtatgctg ccacctacgc ccacaggcag ggcacactgg gcagccagcc			2304
tgccggcagg acttgctgc ctctctctct cagtattctc tccaaagatt gaaatgtgaa			2364
gccccagccc caccctctgc ccttcagcct actgggccag gccggacctg cccctcagt			2424
gtctctccct ccgagtgccc caagatggag acccctttct acaggatgac cccttgatat			2484
ttgcacaggg atattttctaa gaaacgcaga ggccagcggt cctggcctct gcagccaaca			2544
cagtagaaaa ggctgctgtg gttttttaaa ggcagttgtc cactagtgtc ctaggccact			2604
gcagagggca gactgctggt ctccacagat acctgctggt ctcagctcca gcttcaaacc			2664
tcgag			2669

<210> 10

<211> 681
 <212> PRT
 <213> Homo sapiens

<400> 10

Met	Phe	Arg	Lys	Lys	Lys	Lys	Lys	Arg	Pro	Glu	Ile	Ser	Ala	Pro	Gln
1				5					10					15	
Asn	Phe	Gln	His	Arg	Val	His	Thr	Ser	Phe	Asp	Pro	Lys	Glu	Gly	Lys
			20					25					30		
Phe	Val	Gly	Leu	Pro	Pro	Gln	Trp	Gln	Asn	Ile	Leu	Asp	Thr	Leu	Arg
		35					40					45			
Arg	Pro	Lys	Pro	Val	Val	Asp	Pro	Ser	Arg	Ile	Thr	Arg	Val	Gln	Leu
		50				55					60				
Gln	Pro	Met	Lys	Thr	Val	Val	Arg	Gly	Ser	Ala	Met	Pro	Val	Asp	Gly
		65			70					75				80	
Tyr	Ile	Ser	Gly	Leu	Leu	Asn	Asp	Ile	Gln	Lys	Leu	Ser	Val	Ile	Ser
			85						90					95	
Ser	Asn	Thr	Leu	Arg	Gly	Arg	Ser	Pro	Thr	Ser	Arg	Arg	Arg	Ala	Gln
			100					105						110	
Ser	Leu	Gly	Leu	Leu	Gly	Asp	Glu	His	Trp	Ala	Thr	Asp	Pro	Asp	Met
		115					120					125			
Tyr	Leu	Gln	Ser	Pro	Gln	Ser	Glu	Arg	Thr	Asp	Pro	His	Gly	Leu	Tyr
		130				135					140				
Leu	Ser	Cys	Asn	Gly	Gly	Thr	Pro	Ala	Gly	His	Lys	Gln	Met	Pro	Trp
		145			150					155				160	
Pro	Glu	Pro	Gln	Ser	Pro	Arg	Val	Leu	Pro	Asn	Gly	Leu	Ala	Ala	Lys
			165					170						175	
Ala	Gln	Ser	Leu	Gly	Pro	Ala	Glu	Phe	Gln	Gly	Ala	Ser	Gln	Arg	Cys
			180				185						190		
Leu	Gln	Leu	Gly	Ala	Cys	Leu	Gln	Ser	Ser	Pro	Pro	Gly	Ala	Ser	Pro
		195					200					205			
Pro	Thr	Gly	Thr	Asn	Arg	His	Gly	Met	Lys	Ala	Ala	Lys	His	Gly	Ser
		210				215						220			
Glu	Glu	Ala	Arg	Pro	Gln	Ser	Cys	Leu	Val	Gly	Ser	Ala	Thr	Gly	Arg
		225			230					235				240	
Pro	Gly	Gly	Glu	Gly	Ser	Pro	Ser	Pro	Lys	Thr	Arg	Glu	Ser	Ser	Leu
			245						250					255	
Lys	Arg	Arg	Leu	Phe	Arg	Ser	Met	Phe	Leu	Ser	Thr	Ala	Ala	Thr	Ala
			260					265						270	
Pro	Pro	Ser	Ser	Ser	Lys	Pro	Gly	Pro	Pro	Pro	Gln	Ser	Lys	Pro	Asn
		275					280					285			
Ser	Ser	Phe	Arg	Pro	Pro	Gln	Lys	Asp	Asn	Pro	Pro	Ser	Leu	Val	Ala
		290				295						300			
Lys	Ala	Gln	Ser	Leu	Pro	Ser	Asp	Gln	Pro	Val	Gly	Thr	Phe	Ser	Pro
		305			310					315				320	
Leu	Thr	Thr	Ser	Asp	Thr	Ser	Ser	Pro	Gln	Lys	Ser	Leu	Arg	Thr	Ala
			325						330					335	
Pro	Ala	Thr	Gly	Gln	Leu	Pro	Gly	Arg	Ser	Ser	Pro	Ala	Gly	Ser	Pro

<212> DNA

<213> Homo sapiens

<400> 11

```
tccccaccaa aaaattgtgc ccaagaaacc gtctgtgtcc cctgtgccaa ggtttcgggt 60
ttaaagaaac cccccaacaa gggaaacott ctttcttaaa ttggtttggg tgtgaacctt 120
tcccttccaa gtcttgggca tccccccaaa tcaattcatg cgttagccaa ccagaaaaat 180
gcctgcaacc atccaaaaga aaaaagttaa aagcagtctc accacaggca agtgcttttc 240
aagcttaggt tgaattctca agtgtgcoot ccttccoctg tgtaagcca aagtttcagc 300
cagaaggggc ttgggcctgt gcccaacctg cccacccccg ttttgctttg tttccacttc 360
agggcttaag gctcacatca tctcttttca agctggcaag gagaaacggc agggctctggc 420
tctctgaggg ggagtcctt tctttcttct tcntgggtgc tctttgtagg aaagctcctc 480
ccctagatga attgctgca gatggagatg ctagaggggc gacagtaaca gctggcatgg 540
cctgtttgac ttaaccttgg ggccccatgg ctggtgcagc agccacctcc ctgagcccag 600
tggccttgga gacatggatg ggaaaaggag coctggaaat ggcaagcgga ggccctggct 660
gaccgggtgg gagtgtctct aggacacagc ctgatgtctg ggagaggcag ggcatgtttt 720
gtcctgggtg attcactcgc gatgactggg gcaacactgg tcccgttcag gtggatgaac 780
gtctcttagg cactcagcct ccatggatca ctcttctctg tatttaaaaa tattttgttt 840
ttggccggac gcggtggctc acgctgtaa tcccagcact ttgggagggt gaaggcgggt 900
ggatcacctg aggtcaggag ttcaagatca gccagccaa catggtgaaa ccctatctct 960
actaaaaata caaaaattag cggagctgg tgggtgcacac ctatagtctc agctacttgg 1020
gaggctgagg caggagaatc acttgaacct ggaaggcaga ggttgcagtg agccaagatc 1080
gcaccactgt actccagcct gggcaacaga gtgaaacgct gtctcaaaaa aaaaaaaaaa 1140
aaaaaaaaat tgtttttttt tagagaagca atccgtctgc tttaaggaaa acttagaaaa 1200
agagtagaaa gatagaatag aaggagatca cctgtagccc caccaggtaa atgggacaac 1260
taatattgtt atgtatttcc ttcaaatagc cattgtattc aactgcatt gacaaattac 1320
cattggcaaa atcttttaaa accccctacc cctaattctat atcatcaaga attccacttt 1380
cgccaaagta aaccttgata gtttaatttg tgtctgggac ccatgactgt ggacagggtt 1440
aggccccagc aggtcgtggg atccaggaga gaccaccaa tccggccctc cataatgatc 1500
aactagacc tgaggagggt gagagtcagg ctacgggtac ccgccgtcac tcccaccagc 1560
tttattattt tacctttcac attgaggttt gtgatctgtc tgcataattt tggagtatga 1620
tatgagctca ttcttccggg tttatttttt ttccatgcag atatcaaatt acttcagcta 1680
catttattaa aaacatcatc cattccccca gcatgttgca gggtcacctt tgtcattaat 1740
caaatgacct cataagagtg ggtctatttt tggattctct cttctgttcc attgggtctat 1800
ttgtcaattc cgtactaaat ttgccaattt ttgcctattt gcctattgcc tatttgccaa 1860
ttccatacta aattaattat tgtagctttc taataaatct taatatctat ttagtacaat 1920
cctccaactt cgttcattaa gattgtcttg gctattcctg gttctttata tttctgtata 1980
catttttaga tcagttcatc aatttctacc aaaggaaata tgctgggatt ttgtttgaga 2040
tttaaatata tctgcagggt aacttgggaa taattgacat ctttacagta ttgaaccttc 2100
tcacttatga acattcttta atatctttaa taatgttttg tattttccaa tataaggact 2160
ttgtattttt ttgttagatt tattctagat attttgtatt tttaatgtaa aatgatattc 2220
ttttaaaaaa ttcatTTTTT tttttgagac agagtctcgc tctgtcgccc aggctggaat 2280
gcagtggcct gatctcagct cactgcaagc tccgcctccc aggttcacgc cattctcctg 2340
cctcagcctc ctgagtagct gggactacag gtgccacca ccacaccgg ctaatgtttt 2400
gtagttttag tagagacggg gtttcacogt gttagccagg atgatctcta tctcctgacc 2460
tcgtgattcg cccacctcgg cctcccaaag tgctgggatt acaggcgtga gccaccgcgc 2520
ctggcccttt ttaaaaaatt catgttggtt ctggtatgta gaaatccagt tgatttttta 2580
aaatattgac cttgagcctg ggcacgggtg ctoatgcctg taatcccagc actttgggag 2640
```

gctgaggcgg	gtggatcatg	aagtcaagag	atcgagacca	tcctggccaa	catggtgaaa	2700
ccccatctct	actaaaaata	caaaaattag	ctgggcgtga	tggcgtgogc	ctgtagtccc	2760
agctactcag	taggctaagg	caggagaatc	acttgaaccc	gggaggcaga	gattgcagtg	2820
agctgagatc	acaccactgc	actccagccc	gggcaagaca	gcgagactcc	atctcaaaaa	2880
atatatatat	atatattgac	cttgaatcag	ggaccttcta	aattcactcc	cttaatccca	2940
gttttatgta	gattctcccc	cattttctac	ttacacagtt	atgttgtecc	acacagtggt	3000
ggcctcacca	catttcagat	gagtccatgc	tgctccctt	taggtggttg	attggttgat	3060
tttccagacc	taagtgatgg	cctctggttt	ctaaagctct	actccctagc	cccaaaagcc	3120
tgagctcagc	tgattgcttc	tgccaaactcc	caccctcacc	atcaccactc	ctggccctgg	3180
gacaccctct	gggctgtcct	tctttcttct	ccagcctccc	tgctgcctct	gggaagaact	3240
tgttccggaa	tggctcaacta	ttagaatgga	ctcaagagag	gctcccagag	tcagagacca	3300
tttgctaaag	atgctctccc	tgtgcatccc	cacagcaaaa	gctgagcgct	tgggtggggc	3360
aggggagttg	gggagagggc	tgttctgggg	tgggtggtgg	ggggccggtt	caccagctct	3420
tcttcagctg	cagtctgtgt	ccctgcacct	ccagaagatt	tcacagagct	agggaggagg	3480
gcgaaacagg	cagctcaact	aatccaggga	tagcaggtct	atccaaggga	ctgggggaat	3540
agacctgctg	aataaagact	cttctgtagc	aaaaggcaaa	ggctgtaatc	ccagcacttt	3600
gggagaccaa	ggcaggtgga	tcatttgaag	tcagaagtcc	gagaccagcc	tggccaacat	3660
ggtgaaatcc	cgtctctact	aaaaatacaa	aaattagccg	ggtatgttgg	tgggtgcctg	3720
taatctcagc	tattcaggag	gctgaggcaa	gagaatcact	tgaaccgggg	aggtggaggt	3780
tgcaagtgcg	ccagatggtg	ccactacact	ccagtctggg	cgacaggggc	gcaagactcc	3840
ttctcaaaaa	caacaacaac	aacaacaaac	aacaacaaaa	aaggcaaagg	ccaaaaggag	3900
gaggacaaat	tttaccaaac	catgatgtat	atatggcgag	gtccccaggt	cccagacccc	3960
tgacatcagg	catgaccctt	ttgactggta	agtctgagca	gaaagtgggt	tgggtgttact	4020
cccagacttg	tatctgcccc	agtgccagtg	tctggagggc	ctgagcttca	agacagggat	4080
tcaaagagag	gtgacatcac	aagagaaaca	accgtcatgt	atggggactc	tgcttacttc	4140
acacacccta	aaccctatga	gctgtctttc	attaaccccc	ctggctcaga	tcatttccagt	4200
tatttgttca	aaatctctcc	aaattattag	tgggagactc	cctacaactc	atctgcaact	4260
cacacagggt	gttttattcc	aaagggtttg	gtctgtaagg	gtcctgtaca	tgtggctcta	4320
cctctagggg	gtgttcgggtg	gatcccgaac	ctcaagaccc	agaagcatgg	ctgacattga	4380
gatgtgacgt	gggctctgat	tgagtcacgc	atggtgaatt	cctagtgggg	aaccactggc	4440
tgtccagggt	cctgcctttt	ctgccagctg	cctcccagat	ctgogacctc	cttcagaacc	4500
tgccaaaatg	actaggaaaa	tgtgttttcc	atagcaagag	ccaaaagaga	acatgacggc	4560
cctgcactcc	agatcttcgg	gcggatgagt	aatccaagct	ttcagttcaa	gaatcatgtt	4620
tcagtttctt	gaagcctgga	agtgcctttt	tcagatacat	aagaaccag	tgagctgttc	4680
tgagcctctt	cagatccaaa	agcattcaag	aggcagccct	ggccctgtct	gccatcaaca	4740
tgtgatccca	ggtccgggat	cccctgaagg	cgaaactaga	gcaacccttt	ggaaagtgtc	4800
ctccctctcc	caggccccca	gttccccact	ctcagatcta	cccatgctat	ccattgcaag	4860
cctgtgtcac	ttctgtgtat	gcagctcagc	acgaccttag	gcaaagccag	aatcagcaag	4920
gcacgggaca	caggcttgat	tgcaaggtaa	gtgttttatt	gtttgttttt	tgagacagag	4980
tctcattctg	ttgcccaggc	tggagtgcag	tggggcaatc	tcagctcact	gcagcctcag	5040
cctcctgggt	tcaagcgatt	ctcctccctc	aaccccatgg	gtatccggga	ctacaggcac	5100
gtgccaccag	gcccgctaa	tttctttgta	tttttagtca	agacagggtt	tcaccatgtt	5160
ggccaagctg	gtctcaaact	cctgacctca	ggtgatccac	cgcctcggc	ctcccagagt	5220
actaggatta	caggcatgaa	ccaccatgcc	cggcccaggt	gatgttttac	atagagctcc	5280
aataccagag	agaagagtgt	caaggggagg	tgggtctctc	tgcttctctc	ggagagcttt	5340
accctaagt	tagctgcccc	tcacccaccc	caggctatcc	tcttggctca	gggcctttct	5400
ggaattgagg	taaagcacat	ggttaaccatg	aaggcccttt	gggggctccc	tgatacataa	5460
tagtcccaca	ccgggcagca	tgtctgtgat	cagctgggtg	gctttttatt	aacgtatcat	5520

attaacaggt	tcaaccatcc	tgggacaaa	ctgagttgta	ataaaaaaaaa	aaagccaaca	5580
aaaaaataac	tttaatatatac	tgttggaattc	aattcgatag	ttttaagatt	ttcatagtta	5640
cgttcctaaa	tgatattgag	tcaaattttc	cttttcttgc	actctcctta	tctgggttta	5700
agaatcaagg	tcatactcgt	ttcataaaac	aagcttgota	actttcctcc	ctctttcccc	5760
atTTTTAAAA	ttcgttgaca	gacagtggaa	tgatacttgt	aatgggcttt	ggattttata	5820
aaaacacacc	cccagagtct	gcctgctcca	taggggactt	ggcacaggca	agaagacacc	5880
tcttttccctt	gtttatagtc	tgcaactggc	tatttatggc	acgtttgttg	tttctgggac	5940
tgttctgctg	ggagccagcc	atttccctga	ggaagcagag	atgaaggtgc	aggcaagccc	6000
taggcttcta	ggggagctgt	gctgggggag	gggagggagc	cctgaacctg	gtgccccagg	6060
ccctgctgca	gccacccctc	tttcccggga	gggagctcaa	ccttactctg	cacttacagg	6120
caccatgttc	cgcaagaaaa	agaagaaacg	ccctgagatc	tcagcgccac	agaacttcca	6180
gcaccgtgtc	cacacctcct	tcgaccccaa	agaaggcaag	tttgtgggcc	tccccccaca	6240
atggcagaac	atcctggaca	cactgcggcg	ccccaaagccc	gtggtggacc	cttcgcgaat	6300
cacacgggtg	cagctccagc	ccatgaaggt	aagagggggc	ggcagggatg	aggttcagcc	6360
tctcccagta	ctcagacaac	catgcctggc	taaacctcag	aaaggccctt	ggaggaacca	6420
cctacttcac	agctatcagt	taatcagctg	ttttaactcc	ctgcctgtca	gcctgccatt	6480
ctctccctgg	gtaagccagg	gcgaaggagg	ctggggagac	cctctctgca	gggtgggtggg	6540
gttgccagat	tcagcacatg	aaaatgtgag	atgctcaatt	gcatttgtat	ttcagatgac	6600
aacgaatagt	cttttaggac	gtgtcccat	caatatttgg	acctgcagcc	ccatagggac	6660
tgagggctct	cccagaccag	gagaatttta	gttgtgaggg	tcacgactag	tagaccaag	6720
agcctggtag	aaggtggggt	cagggggcct	atcagggttt	ggaggctgcg	aagccagtgt	6780
gtgtggagga	gcccccgcc	tgggtgtctct	tcctcagagg	gctgggcaca	tctctcccag	6840
ccaccctgtg	agctagagaa	tggagccccg	ccccctgagc	tccagctccc	tggcccagcc	6900
gaccacaccc	ctgggcatgc	tggatgcagc	cccatggcac	tcaccatctg	ctctgctgac	6960
gotgggcett	ctccccgc	ccctgcctcc	agcacaggcg	ggacccaagg	tgggcccctga	7020
taaattatgg	aaaaattaat	gggtggatga	cacagcaggg	aaggtcctta	ggtggctctc	7080
cccagggccc	ccagggacat	tctctgaccc	tgatctccca	gccaccctc	cctgccacaa	7140
ttgggcagct	cccacacact	cttttctctt	ccccctacag	acagtgtgtc	ggggcagcgc	7200
gatgcctgtg	gatggctaca	tctcggggct	gctcaacgac	atccagaagt	tgtcagtc	7260
cagctccaac	accctgcgtg	gccgcagccc	caccagccgg	cggcgggcac	agtccctggg	7320
gctgctgggg	gatgagcact	gggccaccga	cccagacatg	tacctccaga	gccccagtc	7380
tgagcgcact	gacccccacg	gcctctacct	cagctgcaac	gggggcacac	cagcaggcca	7440
caagcagatg	ccgtggcccc	agccacagag	cccacgggtc	ctgcccaatg	ggctggctgc	7500
aaaggcacag	tccctgggccc	ccgccgagtt	tcaggggtgc	tcgcagcgc	gtctgcagct	7560
gggtgcctgc	ctgcagagct	ccccaccagg	agcctcgccc	cccacgggca	ccaataggca	7620
tggaatgaag	gctgccaaagc	atggctctga	ggaggcccg	ccacagtcct	gcctgggtggg	7680
ctcagccaca	ggcaggccag	gtggggaagg	cagccctagc	cctaagaccc	gggagagcag	7740
cctgaagcgc	aggctattcc	gaagcatgtt	cctgtccact	gctgccacag	cccctccaag	7800
cagcagcaag	ccaggccctc	caccacagag	caaggtaagt	caggagcctg	gcctgcaggt	7860
gtccactggg	gagtgggtgt	agggacacag	gccttgcccta	gccttcccct	tggaggactg	7920
gcaaagaggc	tccctggact	gcttccgcct	aaggcggcag	aaatgtgcac	ggtaacctct	7980
tctctaagga	gggtggctcg	cctcctcctt	ccctcccttc	ctttccttct	tttctctgtg	8040
gctgttgtgt	tgtttcccat	ttctgtcagt	atttgttccc	aagtgtgtgg	ccataggaaa	8100
agctggatth	gcctagtcca	ggggcagcag	gaggccgact	tgtggcatgt	gtgactgctt	8160
cagacgcaca	tttttcttgt	gagaaaggaa	aggggtgaagg	gagccccctg	ggtgacattt	8220
cttggcaggc	agagtggagc	gcaccttttt	gcttcttcca	ggccctccag	catcctgttg	8280
atagtgcag	taacctcttt	tccattttgg	cagaggagga	gactgataga	gagaggggtga	8340
gtcaccacca	ggcatgatgg	agagtgagtc	agagaaggaa	ggtggggagt	gctctggggc	8400

tgccctgtccg	gccccgggccc	tcttggtctca	tgactctttgc	gtatgaagge	tttacaagca	8460
cagcagccac	ttgttcttta	gtccttccct	gggagggtca	aaggcagtc	taagaaacgg	8520
ctgctgacag	tggcatgggt	aatggagcct	cccctccctc	ctgggagggc	tttaagacaa	8580
gcctgggtac	tcccctgtca	tcggtggggt	gagtgtggcc	cagcctgcac	aggggtgtggg	8640
tttggggatg	acccggacta	caacctctct	gggtcactgc	ctgccagctg	aggtactcag	8700
agaaagtctt	gggcgccgc	gcgtgggtggc	tcacgtctgt	agtcccagca	ctttgggagg	8760
ccaaggtgga	tgggtcacga	ggtcaggaga	tcgagaccat	cctcgctaac	acgggtgaaac	8820
ccogtctcta	ctaaaaatac	aaaaaaaaatt	agccggggcg	ggtggcgggc	gcctgtagt	8880
caagctactc	aggaggctga	ggcaggagaa	tggcgtgaac	ccgggaggca	gagcttgccg	8940
tgagctgaga	tcgcaccact	gcactccagc	ctgggggaca	gacagagcga	gactccgtct	9000
caaaaaaaaa	agagaaagtt	ctgagctttg	tgactctag	tcccctacta	ggttaaagga	9060
cagtgggttg	ggatcccat	gggttggtggc	ttgatgtatc	tgtgagagga	acacgagcat	9120
ctgtgagctg	caggggtgtct	ggaaggctgt	gcccctgggg	agactcagcc	agaaaacca	9180
cgtaagatca	ggacagtgc	ccctgctggg	aagggtgagat	tcggagcttg	acctccctct	9240
gtctctcagg	agtccgtctg	cgaggcctca	gggatttgga	gaaaggggtt	gtcaacactg	9300
ggctgggcac	tcatttgcat	ctttctgggc	tcctgccagc	acccacagc	agggggagag	9360
gcctgtccat	ccctgcacaa	tgtactgagt	actcaccatg	ggccactgct	gctgggtatg	9420
ccgggatgtc	ccccatactt	gtgggagcag	gcggtagtta	tctcgagctc	agcaacacca	9480
tacttccaaa	tccaggggag	tggtttcctt	ctgggcaact	cagacacatc	tttcaagatt	9540
tctactctga	agccaagcct	ctcaatggca	agctgagacc	ccccgagctg	ctccggggccg	9600
gggcttctca	gogtccctac	tgcaggcgct	caggtcagtc	catcctttgt	ggtgggctct	9660
ccttgactg	tagcagcctc	cctggcctct	actcactaga	agttggtggt	accctcggtt	9720
ggaataacca	aaaatgcctc	cagacactgc	caaatgtcac	tcgagcacac	ccattaagaa	9780
ccactgcctt	aagcaaattc	aataacagat	ggggagcatc	agccttcctc	ctcctcctcc	9840
accaccacct	acccaggag	tcccagatc	aagccagcag	cccttggcac	tggggctgac	9900
tctggacact	tgcagcagct	tccataacag	cagttaggcc	acagaggcca	tgcagtgtgc	9960
caggcatggc	tgcaggagg	tctgagtata	gactccagg	ctcctgtacc	tagccccagg	10020
cagtgaggcc	tggagtcaact	ctagctaaag	agatcaggaa	gacagggcgt	gggggcacag	10080
agaccaaaga	ggcaagacag	tttttttagga	gcttgccagg	attagacatg	ttccacttag	10140
agtcagaagg	gcaaacattg	gttaagcacc	taccgtgtac	tccgatatat	gtcaaggata	10200
catggcacca	gtgggattgc	agcatgggag	tcagcagcca	cgggcgtcct	gcgggttcca	10260
gtgcctacag	gacaaccaa	caaccacag	ggttatgagg	attacatgag	atagtacgtt	10320
gaaggcactt	gtcaaagtgg	taagccctca	ataaatggct	ttattagtag	tatttgagat	10380
ggcgtctccc	tctttcgccc	aggctggagt	gcagtggcac	aatcttggct	cactgcaacc	10440
tccacctcct	gggttcaagt	gatectccca	ccttagcctc	ccaagtagct	gggattacag	10500
gcacgctcca	ccatacccaa	ctaatttttg	tatttttaga	agagatgggg	tttcaccatg	10560
ttgcccaggc	tgggtcttga	ctcctgacct	caagtgatcc	acctgccttg	gcctcccaaa	10620
gtgctgggat	tacaggcacc	tgagccacca	tgccaggccg	gctttattat	ttttaaaaaat	10680
attatgccat	ggcctctccc	ctttaggata	cttaagggtat	agccccctaa	gcccacagct	10740
ggggagccat	ggctcagggc	gggaaatgag	gcattgctgt	aaatgtatgc	atgactcttc	10800
tagtggcttt	cttcccaaga	ggtctatcac	atgagtaact	tcagaattaa	tccagagcct	10860
gtaacaatta	attaattctg	ttgtcgtgtc	cccccttccc	tttcttgtgt	ggcctcacia	10920
gtttcatctg	gtccttgctt	gtgattacat	tgataaaagc	tccctccctg	tggagacagg	10980
cagtgaagcc	aacgaaagga	tgctagagac	cagaccttgc	caggctgaag	accaagccag	11040
ctccccagac	tccccagcct	atgtcccaga	ctctgcttgt	gctgggctcc	tggctgggcc	11100
atccctcccc	cagcctccag	acgcaggctc	cgccctgagc	ccagccagca	cctgcagcag	11160
cagcagcagc	acagggaact	ggcctgtgga	gacaggggag	aaaccctac	ctcagcctgt	11220
ccacgtggta	cccacacatc	ctcagagtag	agctggccca	tgcagaagcc	ctcaaggcca	11280

```

ggaggggaat gatctcattt tacagccttt cttaggagct tcaggatgag aggtcatcag 11340
agccacctca ggaggagctt taggtggtcc ccaagcttct gccccgaccc acctggatgg 11400
gtgcctggag agcatgtttt ctgagttaag tccacactca ggccagcagg cagcttcctt 11460
agagccccga gcctttctac aggttgactg tgtgatgcag tgagccctgc cccacttccc 11520
tccctgtccc tgcttggtga cgtctcatgg aacctctgtt cccaggacct ggtatcacag 11580
cctcagtcac ggccatgcgc cctccacccc cctcacagcc ctcccagagg ctccctgagg 11640
ccgtaagatc atactgcccc cttatgcaga gtttctcaaa gtatgttcca tgggcctcct 11700
aggaccagg gacctgttcc aaatgcagtc tctgctctag gctcccaccg aatcaggctc 11760
tgaggcggga agtctgcggt ttctctagct cccagatct ctgcacacgt ccctgcattg 11820
tagtggagac aggtcagag aggatgactt gcctaaggct catcacaggg cagagcagcc 11880
cagggtggg cccaggtcc tgacagcccc gtccaggggt cccactgtct cactacacag 11940
tggatggtga cagtgtcaca gtgtcacagt ggatggtgac agtcagggtc tggcgaggac 12000
atgggagaat gtttactgtc caaatgtact catcagggat ggagtgagtc caggcagtc 12060
tgggaggatt gctagcttct ttctgtgaa ggtcaagcac acactcgggt gggcaggcag 12120
gtgtgggggt ggcagaagtc tgccccagca tggctgtcgg ccagcaggag tgcctattcc 12180
accctaagca ggccagggac ttggctggag agtagaagcc ctgaagctgc ggggggtcgg 12240
ggaaggaagg gagtgagggt tgccaaagac actgaaaaga ctctggtggg gcccaaggcc 12300
cagatttggg gtttggggtc cctgagcaag catcccagcc caaacttact gcttgagatt 12360
tcctgtaagt tgtttcagct atgggatcag gaccaggacc cactgggcac ctaagacaat 12420
ggcttacatg atgggttttg agaagttcct agaaggtttt ttctgcatcc cctgaagcat 12480
ccctctccag gtgcccttta aaaacacgta atccctggga ggggtcatgg tgcatacac 12540
cgctccttgg ggagaaccca aagatgggct ggcaccttct ctgtcagaaa gagcagaagg 12600
gcttgggctc ggaaaagcaa gaagcctcgc aggtctccag ggctgggctt gagcagggt 12660
cactgggggc ccaggctgcc cctcagctcc accttccctt cctccctccc tgcagagcc 12720
aatgaggata ggccccctac cttctcctcc ctcccgggg ctccctagcc aggagtttca 12780
tgccagggag gaagtggaag gactccttta ggggtcctt aagacatctc cccatccctg 12840
gcctcaaggc ttgggttttg ctggacctac cctcctaact ccagatctct ctggcaccag 12900
attcccagcc caggggagac acctgagaac ccccagatg gtgacacacc tctgtggtcc 12960
tctgtcaggg acataacctc ccagcacaga tttgcaaact ccctgctgca ggcacaggca 13020
gggctatcgg gccccagggt tggctccctt gccttgggtc agggagtggg gacacagttg 13080
cccactgtct cccacccac tgccaggcct cttctgcccc catgggtcct ggggtggggg 13140
agccttggga gtgaagaatg cctctgacct agattcttca agcagcctct gagctcagag 13200
gaagagtctg cctcacggca gctcctctgg ggtctagctg tcaatcgccc aggaagaaat 13260
accagcgca ggaccggcg gggagctggc cttctctgtc ttcccagggt cagcagagcg 13320
agtgtgaagg gctgtcttgg gctgcccag cctggtgccc tgcgggggac tgcctggcaca 13380
ggactgtgac tgggcttcag ctctgtctga aaatctttgc tcagagcacc tccctagttt 13440
gatctgatac cccgcctgac cctgccagag tccagaggtc acggcggcca gccctgcct 13500
ccgggaaggt tattccaaat gctcccacag ccctgacctt tctgttgct ttgtccctgc 13560
agcccaactc ctctttccga ccgccgcaga aagacaacct cccaagcctg gtggccaagg 13620
cccagtcctt gccctcggac cagccgggtg ggaccttcag ccctctgacc acttcggata 13680
ccagcagccc ccagaagtcc ctccgcacag ccccgccac aggcagctt ccaggccggt 13740
cttccccagc gggatcccc cgcacctggc acgccagat cagcaccagc aacctgtacc 13800
tgccccagga cccacgggtt gccaaagggt cctggtctg tgaggacaca ggtgttggtga 13860
cacatgagca gttcaaggct gcgctcagga tgggtggtga ccagggtgac ccccggtgc 13920
tgctggacag ctacgtgaag attggcgagg gctccaccgg catcgtctgc ttggcccggt 13980
agaagcactc gggcgccag gtggccgtca agatgatgga cctcaggaag cagcagcgca 14040
gggagctgct cttcaacgag gtgggaggac aggggtgggac acagacgggg gcgttgggga 14100
tgggcagtga gcagccagcc aggctggaca tctgtgagca ggggcagtgg gtggccatgc 14160

```



```

tcacggatag agccagatct ggatcactga tgccaatcct ctgccccctc cacagagcta 17100
tagcatctga atgctgagag ccttgagggg gtggggaggg acaagggaac aggaagttaa 17160
aaaaccagcg aattcatgac tttcaaacia tgataagtcc aggcaatcag gtcaccccga 17220
agtgactgca aattgtggct tcatcttact gccctgcctc tacaggtctc cccagtgtctg 17280
cgagacttcc tggagcggat gctggtgcgg gaccccccaag agagagccac agcccaggag 17340
ctcctagacc accccttcct gctgcagaca gggctacctg agtgccctggg gccctgatc 17400
cagctctacc gaaagcagac ctccacctgc tgagcccacc ccaagtatgc ctgccaccta 17460
cgcccacagg cagggcacac tgggcagcca gcctgcoggc aggacttgcc tgcctcctcc 17520
tctcagtatt ctctccaaag attgaaatgt gaagcccag cccaccctc tgccttcag 17580
cctactgggc caggccggac ctgccccctc agtgtctctc cctcccgagt cccagatgg 17640
agaccccttt ctacaggatg accccttgat atttgacag ggatatttct aagaaacgca 17700
gaggccagcg ttcctggcct ctgcagccaa cacagtagaa aaggctgctg tggtttttta 17760
aaggcagttg tccactagtg tcctaggcca ctgcagaggg cagactgctg gtctccacag 17820
atacctgctg ttctcagctc cagcttcaaa cctcgagtct cgagaggggc acggggtggg 17880
ttttatgacc ggaatccgc ttcctccctc acgtctgatg tcctgaagggt gcagtccac 17940
ctgtacagcc cctccccgc cagaactgtg aatggcctgc tccaggccat ggctgggggc 18000
agggagttag gggacaattt ctgagtgaag gagaaagaat ggggtcgggt gtgaagggtg 18060
tctcacttta cagaatggag agaacatcgt gtgtgtgtgt gtgtgtgtgt 18120
gtgtgtgttaa ggggaggaag gccacctga cagcccaggt cctccaggt caccacagc 18180
cagtttcagg aaggctgccc ctctctccca ctaagttctg gcctgaagggt acctgctttc 18240
ttggcctggc ttcacctct cactcctgt gtctacctg ccagtggagt ggtccatgt 18300
aagtctaaca ctctgggag ctcaggaggc ttctgagctt ctctgtact gtgcacgtg 18360
agggccagag acaggaatgt aaggattggc aactgtgtta cctttcaagt ttatctcaat 18420
aaccaggtca tcagggaccc attgttctct tcagaaccct atctgggaga gaaggcgaac 18480
cacctccggg tttccatcat gtcaagggtc caggcatcca tgtgtgcaaa ccatctgccc 18540
cagctgcctc cacagactgc tgtctccttg tctcctcgg ccctgcccc cttcagggt 18600
gctgtgagat ggaattccag gaaagaactt caggtgtctg gaccctttct atctagataa 18660
tattttttaga ttcttctgct ccctagtgc ctacctggg gcaaagaaat tgcaaggact 18720
tttttttaag ggctcagagt ttcaaaacia aagcatctc cctagaaatt tttgtgaatt 18780
gtttgcactt gtgcctgttt taaattaaat tgagtgttca aagccattgg gcttctctgt 18840
tctctgggag cggagaccgg cgtctctgga ggggggtctc ctgtggcggg tgaatctcgt 18900
gtagcctccc ctctcccca cgtgagctct ccagcagcca caccacagaa caccacactt 18960
ccctggtggc ctgtggaccc gaaaggaggg cagagaggaa gggaaacagg aagtgaagg 19020
cccttgggaa tgaaggcg 19038

```

<210> 12
 <211> 146
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (2)..(145)

<400> 12
 g cac cgg gat atc aag ggg cag aat gtg ctg ctg aca gag aat gct gag 49
 His Arg Asp Ile Lys Gly Gln Asn Val Leu Leu Thr Glu Asn Ala Glu

1

5

10

15

gtc aag cta gtg gat ttt ggg gtg agt gct cag gtg gac cgc acc gtg 97
 Val Lys Leu Val Asp Phe Gly Val Ser Ala Gln Val Asp Arg Thr Val
 20 25 30

ggc aga cgg aac act ttc att ggg act ccc tac tgg atg gcc ccc gag g 146
 Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu
 35 40 45

<210> 13

<211> 48

<212> PRT

<213> Homo sapiens

<400> 13

His Arg Asp Ile Lys Gly Gln Asn Val Leu Leu Thr Glu Asn Ala Glu
 1 5 10 15

Val Lys Leu Val Asp Phe Gly Val Ser Ala Gln Val Asp Arg Thr Val
 20 25 30

Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr Trp Met Ala Pro Glu
 35 40 45

<210> 14

<211> 18

<212> DNA

<213> Homo sapiens

<400> 14

atgcamcang ayathaar

18

<210> 15

<211> 20

<212> DNA

<213> Homo sapiens

<400> 15

gcnacytcng gngccatcca

20

<210> 16

<211> 27

<212> DNA
<213> Homo sapiens

<400> 16
cccgaattca tgcamcanga yathaar

27

<210> 17
<211> 29
<212> DNA
<213> Homo sapiens

<400> 17
cccgaattcg cnacytcngg ngccatcca

29

<210> 18
<211> 17
<212> DNA
<213> Homo sapiens

<400> 18
gagtgaactcc atcctgc

17

<210> 19
<211> 17
<212> DNA
<213> Homo sapiens

<400> 19
gtaggggggtt cccacca

17